Survivin启动子马区动CD/TK双自杀基因对胃癌的靶向治疗作用
|
摘要
胃癌是临床最常见的消化道恶性肿瘤之一,全世界每年大约有100多万新发胃癌患者,在我国其发病率和病死率均为全身恶性肿瘤的首位,在国内某些地区已居全部恶性肿瘤死亡原因之首。近年来,随着胃癌相关研究的不断深入,人们在胃癌的发病机制和临床诊治方面取得了大量的成果,但目前,胃癌的诊治仍面临许多困难,整体治疗效果仍不理想,其临床特点依然表现为三低一高,即早期诊断率低(约10%),手术切除率低(<70%),5年生存率低(约40%),根治术后复发转移率高(约50%)。因此,积极寻找新的胃癌治疗手段,提高胃癌的治疗水平,具有积极而重要的现实意义。
肿瘤基因治疗通常是指把正常的目的基因利用载体及基因转化方法导入患者体内,利用基因的功能抑制肿瘤细胞生长或杀死肿瘤细胞。自杀基因疗法又称为基因介导的酶前药治疗——GDE(Gene-directed enzyne prodrug treatment),已经成为手术治疗、放射治疗、化疗等传统肿瘤疗法后的一种新的抗肿瘤治疗措施。自杀基因(suicide gene)是指来自病毒和细菌等的一类可以将生物前药转换成有毒产物的基因。此类基因编码的特异性酶类,可以将对细胞本来没有毒或毒性极低的药物前体,在肿瘤细胞内代谢成毒性产物,杀死肿瘤细胞,导致这些细胞自杀。来源于大肠杆菌的胞嘧啶脱氨酶基因(E.coli cytosine deaminase, CD)及来源于病毒的单纯疱疹病毒胸苷激酶基因(herpes simplex virus thymidine kinase, HSV-TK)是目前研究应用较多的两类自杀基因。大肠杆菌胞嘧啶脱氨酶基因编码的酶为胞嘧啶脱氨酶(cytosine deaminase),可激活5-氟胞嘧啶,变成5-氟尿嘧啶,从而抑制DNA和RNA的合成,发挥细胞毒作用。单纯疱疹病毒胸苷激酶基因编码胸苷激酶,可将核苷类似物代谢为二磷酸化物,进一步代谢为对细胞有毒性的三磷酸化合物,进而抑制DNA聚合酶发挥抗肿瘤作用。胃癌自杀基因治疗是指将自杀基因克隆至适当表达载体,然后导入胃癌细胞,自杀基因编码的特异性酶可以将无毒的药物前体代谢成毒性产物,达到杀死胃癌细胞的目的。
在肿瘤基因治疗的研究中,基因的靶向性表达是亟需解决的关键问题之一。靶向性表达是指目的基因仅在肿瘤细胞表达,在正常细胞中不表达,从而减少对正常细胞的影响。有些基因的启动子能在肿瘤细胞中特异表达,而在正常细胞中不表达,利用这些启动子序列构建能在肿瘤细胞中特异表达的载体,让目的基因在肿瘤细胞中的特异表达,特异杀死肿瘤细胞,是目前肿瘤基因治疗靶向性的一个有效途径。目前在肿瘤研究中应用的启动子主要有：端粒酶基因启动子、癌胚抗原(CEA)启动子等,但这些启动子存在明显的缺点,如调控作用弱、应用范围窄、特异性不高等。
Survivin是凋亡抑制蛋白家族中的一员,它在多数肿瘤中高表达,但是在成人正常终末分化组织中不表达或者是低表达,具有明显的肿瘤特异性。因此利用survivn特异启动子可以驱动下游目的基因在肿瘤细胞中的特异表达,从而避免对正常细胞的损伤。
鉴于上述,在本实验中我们克隆了Survivin启动子,构建了Survivin启动子介导的CD/TK表达载体,转染至胃癌细胞,建立3ALB/C裸鼠胃癌模型,给予一定浓度的5-FC、GCV,证实了Survivin-CD/TK系统对裸鼠的胃癌皮下移植瘤有明显的靶向杀伤作用。
本论文分为四部分：
第一部分Survivin启动子的克隆及在胃癌细胞中的特异表达
目的
利用分子克隆技术,构建survivin介导的EGFP基因重组真核表达质粒,转染胃癌细胞,鉴定survivin启动子在胃癌细胞的特异表达。
方法
1.从人外周血白细胞中提取基因组DNA,设计合适引物,通过PCR扩增出survivin启动子并与pMD18-T载体连接,经筛选得到重组质粒pMD-survivin,进行酶切鉴定及测序。
2.提取质粒pMD-survivin,酶切获得survivin启动子片段。采用同样酶切真核表达载体pEGFP-Cl,连接,转化细菌,构建重组真核表达载体pEGFP-Su,酶切鉴定。
3.脂质体转化胃癌SGC7901细胞及正常胃上皮细胞株GES-1,72小时后荧光显微镜下观察EGFP的表达情况。
结果
1.经酶切和测序证实成功获得survivin启动子(约910bp)。
2.经酶切鉴定成功构建重组质粒pEGFP-Su。
3.荧光显微镜下观察,survivin启动子介导的EGFP能特异在胃癌SGC7901细胞表达,而在正常的胃上皮GES-1细胞没有活性。
第二部分重组pEGS-CD/TK双自杀基因载体的构建与鉴定
目的
利用分子克隆技术,构建pEGS-CD/TK双自杀基因载体。方法
1.提取JE.coli BL21基因组DNA,设计合适引物,通过PCR扩增出CD基因并与pMD18-T载体连接,经筛选得到重组质粒pMD-CD,进行酶切鉴定及测序。
2.提取pORF-HSVtk质粒,设计合适引物,通过PCR扩增出TK基因并与PMD18-T载体连接,经筛选得到重组质粒pMD-TK,进行酶切鉴定及测序。
3.将质粒pMD-CD进行双酶切,获得CD基因片段,连接与相同酶切的真核表达载体pEGFP-Su上,构建重组真核表达载体pEGS-CD,酶切鉴定。4.再将质粒pMD-TK进行双酶切,获得TK基因片段,连接与相同酶切的真核表达载体pEGS-CD上,构建重组真核表达载体pEGS-CD/TK,酶切鉴定。
结果
1.经酶切和测序证实成功获得CD基因(约1281bp),TK基因(约1161bp)。
2.经酶切鉴定成功构建重组质粒pEGS-CD。
3.经酶切鉴定成功构建重组质粒pEGS-CD/TK。
第三部分pEGS-CD/TK双自杀基因载体对胃癌SGC7901细胞的体外杀伤作用
目的
利用细胞转染技术,研究survivin启动子介导的CD/TK双自杀基因系统对胃癌细胞SGC7901的体外杀伤作用。
方法
1.利用脂质体转染技术,将pEGS-CD/TK双自杀基因质粒转染胃癌SGC7901细胞、GES-1细胞。
2. SGC790、GES-1细胞加入不同浓度的5-FC、GCV前体药物。MTT方法测定吸收值,计算细胞存活率。
3.转染和未转染pEGS-CD/TK的SGC7901细胞混合,加入5-FC+GCV二者混合液,观察有无旁观者效应。
4.应用RT-PCR检测转染细胞中CD、TK基因mRNA的表达；Western blot法检测转染细胞CD、TK蛋白的表达。
5.流式细胞术检测细胞凋亡率。
结果
1.在给予5-FC、GCV后并达到一定浓度时,5-FC和GCV对SGC7901细胞存活率随着药物浓度的升高而呈现下降趋势,其体外杀伤作用具有浓度依赖性,且联合用药对SGC7901细胞体外的杀伤作用要强于二者单独应用；而不同浓度梯度的5-FC和GCV对GES-1细胞的细胞存活率改变不大。
2.转染的SGC7901细胞即可引起大部分未转染的细胞发生凋亡,旁观者效应较为明显。
3.通过RT-PCR和(?) Western blot检测证实CD,TK基因在SGC7901细胞中成功表达。
4.转基因SGC7901细胞在给予前药处理24h后,治疗组SGC7901细胞凋亡率明显高于对照组凋亡率(P<0.01)。
第四部分pEGS-CD/TK双自杀基因系统对胃癌SGC7901细胞裸鼠模型的体内抑瘤效应
目的
观察survivin启动子介导的CD/TK双自杀基因系统对胃癌SGC7901细胞裸鼠模型的体内抑瘤效应。
方法
1.动物模型的建立：小鼠左腋下皮下接种2×106SGC7901细胞,第三天复种一次,建立胃癌动物模型。
2. SGC7901皮下移植术后第10天,实验分为4组,每组10支。分组方法：A组：注射重组pEGS-CD/TK与前药5-FC与GCV；B组：仅注射重组pEGS-CD/TK;C组：仅注射前药5-FC与GCV；D组：空白对照,不施加任何处理。每3天测量一次皮下移植瘤的大小,计算瘤体体积。处死裸小鼠,HE染色,观察肿瘤的病理变化。
3. RT-PCR检测(?)CD/TK基因的表达。
结果
1.接种肿瘤细胞后10天左右,出现皮下肿瘤结节。裸鼠成瘤达0.5cm后开始治疗。注射重组pEGS-CD/TK与前药5-FC与GCV组与仅注射pEGS-CD/TK,前药GCV和5-FC,空白对照组相比较,移植瘤体积明显缩小,有统计学意义(P<0.05)。
2.治疗组切片中可见肿瘤细胞数目稀少,胞浆少,细胞核较小且染色较深,细胞分裂相少,核和胞浆凝缩及坏死区散在分布,纤维血管较少,可见炎性细胞浸润
3.治疗组瘤体内RT-PCR可检测至(?)CD/TK基因表达
结论
1. Survivin启动子能在胃癌肿瘤细胞中特异表达。
2.经酶切和测序鉴定,利用分子克隆技术成功获得CD和TK基因。
3.成功构建重组Survivin启动子介导的CD/TK双自杀载体系统。
4.含CD和TK融合基因的双自杀基因载体对SGC7901细胞具有强烈的杀伤作用,并且存在明显的旁观者效应。治疗组SGC7901细胞凋亡率明显高于对照组凋亡率(P<0.01)。
5. RT-PCR及Western blot检测结果CD/TK基因在SGC7901细胞中成功表达。
6.应用SGC7901细胞可成功建立致瘤BALB/C裸小鼠。7. Survivin启动子介导的CD/TK双自杀基因能在胃癌小鼠的瘤体内特异表达。
8. Survivin启动子介导的CD/TK双自杀基因在前体药物GCV和5-FC作用下,能抑制胃癌瘤体的生长,具备体内抑瘤效应。
Gastric cancer is one of the most common digestive system malignancies in clinical practice. There are more than10million new cancers worldwide every year-Gastric cancer has become the first cause of death of all malignant tumors in some areas of China. In recent years, with the deepening of the stomach cancer research, the pathogenesis and treatment of gastric cancer have made a lot of achievements. However, the diagnosis and treatment of gastric cancer still faces many difficulties, and the overall treatment effect is still not ideal. The clinical characteristics shows "three low and one high", namely the diagnosis is low (about10%), surgical excision rate low (＜70%),5years of survival rate low (about40%), radical surgery relapse and metastasis rate high (about50%).Therefore, to find a new stomach cancer prevention and control method, will have a positive and important practical significance to further improve the overall prevention level and cure of gastric cancer.
Cancer gene therapy is usually transferring the exogenous genes into patients using expression vector and different methods, which produce the product to inhibit and kill cancer cells. Suicide gene therapy, also called gene-directed enzyme prodrug treatment, has become a new anti-tumor therapeutic approach after the traditional surgical resection, radiotherapy, chemical drug treatment.Suicide gene generally refers to the prodrug conversion gene or cytotoxic receptor gene from prokaryote or lower organisms (viruses and bacteria),which encode the specificity enzyme can convert the nontoxic prodrug (or cytotoxic factor) into toxic product (or cytotoxic factor) to achieve the purpose of killing cancer cells. At present, a variety of suicide genes have been found, including Escherichia coli cytosine deaminase (CD), herpes simplex virus-thymidine kinase (HSV-TK). Escherichia coli cytosine deaminase gene encodes the cytosine deaminase, which can convert the cytosine into uracil, change5-Fc into cells toxic metabolites5-Fu, to play cytotoxic effects through inhibiting RNA and DNA synthesis. HSV-TK gene encodes thymidine kinase, which can convert the nucleoside analogue (NA) into bisphosphate iodide, further turn into triphosphate compound to inhibit the DNA polymerases to play antitumor function.
In cancer gene therapy, one of key issues is to improve the targeting expression of therapeutic gene. The targeted expression, is to make the gene function as in tumor cells as possible, and to reduce the influence to normal cells. Specifically expressed promoter sequence in tumor cells has been widely used, which can drive the downstream gene to express in tumor cells specifically, is an effective way to solve the problems of tumor targeted gene therapy. At present, the embryo carcinoma antigen (CEA) promoter, telomerase gene promoter, etc have been used as the regulated element for tumor target gene therapy, but the promoters have some disadvantages, such as application is limited, regulation effect is weak. Survivin is a member of apoptosis inhibiting protein family, it express highly in most tumors, but do not express or lower express in adult normal terminal differentiation tissue, has the obvious tumour specific. Therefore, survivn specific promoter can be used to drive the gene express specific in the tumor cells, to avoid the damage to normal cells.
In the current study, we cloned the survivin promoter and constructed the CD/TK expression vector mediated by survivin promoter, then transfected into gastric cancers cells, established nude BALB/C mouse gastric cancers model, gave certain concentration of5-FC, GCV. We demonstrated that survivin-CD/TK systems have obvious target killing function to gastric cancer subcutaneous BALB/C rats.
Our studies include the following four parts.
Part I:Cloning of survivin promoter and express specific in the gastric cancer cell
Objective:
The aim of this study was to construct the recombinant EGFP expression vector driven by survivin promoter, and identify the promoter activity specific in gastric cancer cells.
Methods:
1. Human genome DNA was extracted from white blood cells. Primers were designed according to the sequence of survivin promoter. Survivin gene promoter was obtained by PCR technology, and ligated into the pMD18-T vector, followed by digestion with restriction endonuclease and sequencing.
2. pMD-survivin vector was digested by double restriction endonuclease to release the survivin fragment, and ligated into the pEGFP-C1vector to generate the recombinant pEGFP-Su, and then identified by enzyme digestion.
3. pEGFP-Su plasmid was transfected into gastric cancer SGC7901cells and normal gastric epithelial GES-1cell, and EGFP gene expression was detected by fluorescence microscope.
Results:
1. Human survivin promoter of910bp long was obtained via PCR method.
2. We constructed the recombinant pEGFP-Su plasmid successfully.
3. EGFP driven by survivin promoter can express specific in SGC7901gastric cancer cells, but not in the normal gastric epithelium GES-1cell.
Part II:Construction and identification of the recombinant pEGS-CD/TK double suicide genes vector
Objective:
To construct and identify the recombinant pEGS-CD/TK plasmid using molecular cloning technology
Methods:
1. E.coli BL21DNA was extracted. Primers were designed according to the sequence of CD gene. CD gene was obtained by PCR technology, and ligated into the pMD18-T vector, followed by digestion with restriction endonuclease and sequencing.
2. pORF-HSVtk was extracted and used as PCR template. Primers were designed according to the sequence of TK gene. TK gene was obtained by PCR technology, and ligated into the pMD18-T vector, followed by digestion with restriction endonuclease and sequencing.
3. pMD-CD vector was digested by double restriction endonuclease to release the CD gene fragment,and ligated into the pEGFP-Su vector to generate the recombinant pEGS-CD, then identified them by enzyme digestion.
4. pMD-TK vector was digested by double restriction endonuclease to release the TK gene fragment, and ligated into the pEGS-CD vector to generate the recombinant pEGS-CD/TK, then identified them by enzyme digestion.
Results:
1. CD gene (1281bp) and TK gene (1161bp) were obtained through PCR method.
2. We constructed the recombinant pEGS-CD plasmid successfully.
3. We constructed the recombinant pEGS-CD/TK plasmid successfully.
Part Ⅲ Killing effect of pEGS-CD/TK double suicide gene vector on the Gastric Cancer Cells in vitro
Objective:
To study the killing effect of CD/TK double suicide genes driven by survivin promoter on the gastric cancer cells in vitro.
Methods:
1. pEGS-CD/TK plasmid was transfected into SGC7901, GES-1cells using the liposome.
2. The prodrug5-FC and GCV were added into the SGC7901, GES-1cells, and then the cell survival rate was determined by MTT methods.
3. The untransfected and transfected SGC7901were mixed, followed by adding the prodrug5-FC, GCV. The bystander effect was observed through MTT methods.
4. CD, TK gene expression was detected by RT-PCR and Western blot.
5. Cell apoptosis rate was detected by flow cytometry.
Results:
1. SGC7901cell survival rate decreased with the concentration5-FC, GCV increased, and the killing effect in vitro showed concentration dependent.The killing effect of drug combination on SGC7901cells was stronger than the drug used alone in vitro. However, the5-FC and GCV had little effect on GES-1cells survival rate.
2. The transfected SGC7901cells can cause the untranfected cells apoptosis, showed the obvious bystander effect.
3. CD, TK gene can express in the transfected in the SGC7901cell through RT-PCR and Western blot assay.
4.The transfected SGC7901cells was treated by the prodrug for24h, SGC7901cell apoptosis rate of the treatment group was significantly higher than that of the control group (P<0.01).
Part IV:Killing effect of pEGS-CD/TK double suicide gene on the nude mice model of gastric cancer cells in vivo
Objective:
To investigate the killing effect of CD/TK double suicide genes on the nude mice model of gastric cancer cells in vivo.
Methods:
1. The nude mice were subcutaneously inoculated by5×106gastric cancer cells, re inoculated at the third day to establish the gastric cancer nude mice model.
2. After10days of SGC7901subcutaneous transplantation, the mice were divided into4groups (n=10). Group A:injected with recombinant pEGS-CD/TK and prodrug5-FC and GCV; Group B:only injected with recombinant pEGS-CD/TK; Group C:only injected prodrug5-FC and GCV; Group D:blank control, no any treatment. The size of the subcutaneous transplantation tumor was measured once every3days. The nude mice was killed and stained by HE method, the tumor pathological changes were observed.
3. CD/TK gene expression was detected by RT-PCR method.
Results:
1.Ten days after tumor cells inoculation, subcutaneous tumor nodules appeared.The treatment began after the nude mice tumor achieved0.5cm.Compared with the only injected pEGS-CD/TK, prodrug GCV and5-FC and blank control group, the transplantable tumor size in the injected with pEGS-CD/TK and prodrug GCV and5-FC group was sigficantly reduced, and showed statistically significant (P＜0.05).
2.Tumor cells number in the treatment group were visible scarce, had scant cytoplasm, nuclear was smaller and staining was deeper, the cell division was fewer, nuclear and cytoplasm condensed and necrotic area were scattered, fiber blood vessels were fewer, inflammatory cells infiltration was visible.
3. CD, TK gene expression could be detected by RT-PCR in the treatment group.
Conclusions
1. Survivin promoter expresses specific in the gastric cancer cells.
2. CD and TK genes have been obtained successfully by gene cloning technology.
3. CD/TK double suicide genes plasmid driven by survivin promoter has been constructed.
4. CD and TK double suicide genes have stronger killing effect on the SGC7901cells, and show the obvious bystander effect.SGC7901cell apoptosis rate of the treatment group is significantly higher than that of the control group (P＜0.01).
5. CD/TK gene express in SGC7901cells successfully.
6. Tumorigenic BALB/C nude mice have been successful established using SGC7901cells.
7. CD/TK double suicide gene driven by Survivin promoter can specifilly express in the gastric cancer cells.
8. CD/TK double suicide gene driven by survivin promoter can inhibit the growth of gastric cancer in the presence of prodrug drug GCV and5-FC, has an inhibitory effect in vivo.
肿瘤基因治疗通常是指把正常的目的基因利用载体及基因转化方法导入患者体内,利用基因的功能抑制肿瘤细胞生长或杀死肿瘤细胞。自杀基因疗法又称为基因介导的酶前药治疗——GDE(Gene-directed enzyne prodrug treatment),已经成为手术治疗、放射治疗、化疗等传统肿瘤疗法后的一种新的抗肿瘤治疗措施。自杀基因(suicide gene)是指来自病毒和细菌等的一类可以将生物前药转换成有毒产物的基因。此类基因编码的特异性酶类,可以将对细胞本来没有毒或毒性极低的药物前体,在肿瘤细胞内代谢成毒性产物,杀死肿瘤细胞,导致这些细胞自杀。来源于大肠杆菌的胞嘧啶脱氨酶基因(E.coli cytosine deaminase, CD)及来源于病毒的单纯疱疹病毒胸苷激酶基因(herpes simplex virus thymidine kinase, HSV-TK)是目前研究应用较多的两类自杀基因。大肠杆菌胞嘧啶脱氨酶基因编码的酶为胞嘧啶脱氨酶(cytosine deaminase),可激活5-氟胞嘧啶,变成5-氟尿嘧啶,从而抑制DNA和RNA的合成,发挥细胞毒作用。单纯疱疹病毒胸苷激酶基因编码胸苷激酶,可将核苷类似物代谢为二磷酸化物,进一步代谢为对细胞有毒性的三磷酸化合物,进而抑制DNA聚合酶发挥抗肿瘤作用。胃癌自杀基因治疗是指将自杀基因克隆至适当表达载体,然后导入胃癌细胞,自杀基因编码的特异性酶可以将无毒的药物前体代谢成毒性产物,达到杀死胃癌细胞的目的。
在肿瘤基因治疗的研究中,基因的靶向性表达是亟需解决的关键问题之一。靶向性表达是指目的基因仅在肿瘤细胞表达,在正常细胞中不表达,从而减少对正常细胞的影响。有些基因的启动子能在肿瘤细胞中特异表达,而在正常细胞中不表达,利用这些启动子序列构建能在肿瘤细胞中特异表达的载体,让目的基因在肿瘤细胞中的特异表达,特异杀死肿瘤细胞,是目前肿瘤基因治疗靶向性的一个有效途径。目前在肿瘤研究中应用的启动子主要有：端粒酶基因启动子、癌胚抗原(CEA)启动子等,但这些启动子存在明显的缺点,如调控作用弱、应用范围窄、特异性不高等。
Survivin是凋亡抑制蛋白家族中的一员,它在多数肿瘤中高表达,但是在成人正常终末分化组织中不表达或者是低表达,具有明显的肿瘤特异性。因此利用survivn特异启动子可以驱动下游目的基因在肿瘤细胞中的特异表达,从而避免对正常细胞的损伤。
鉴于上述,在本实验中我们克隆了Survivin启动子,构建了Survivin启动子介导的CD/TK表达载体,转染至胃癌细胞,建立3ALB/C裸鼠胃癌模型,给予一定浓度的5-FC、GCV,证实了Survivin-CD/TK系统对裸鼠的胃癌皮下移植瘤有明显的靶向杀伤作用。
本论文分为四部分：
第一部分Survivin启动子的克隆及在胃癌细胞中的特异表达
目的
利用分子克隆技术,构建survivin介导的EGFP基因重组真核表达质粒,转染胃癌细胞,鉴定survivin启动子在胃癌细胞的特异表达。
方法
1.从人外周血白细胞中提取基因组DNA,设计合适引物,通过PCR扩增出survivin启动子并与pMD18-T载体连接,经筛选得到重组质粒pMD-survivin,进行酶切鉴定及测序。
2.提取质粒pMD-survivin,酶切获得survivin启动子片段。采用同样酶切真核表达载体pEGFP-Cl,连接,转化细菌,构建重组真核表达载体pEGFP-Su,酶切鉴定。
3.脂质体转化胃癌SGC7901细胞及正常胃上皮细胞株GES-1,72小时后荧光显微镜下观察EGFP的表达情况。
结果
1.经酶切和测序证实成功获得survivin启动子(约910bp)。
2.经酶切鉴定成功构建重组质粒pEGFP-Su。
3.荧光显微镜下观察,survivin启动子介导的EGFP能特异在胃癌SGC7901细胞表达,而在正常的胃上皮GES-1细胞没有活性。
第二部分重组pEGS-CD/TK双自杀基因载体的构建与鉴定
目的
利用分子克隆技术,构建pEGS-CD/TK双自杀基因载体。方法
1.提取JE.coli BL21基因组DNA,设计合适引物,通过PCR扩增出CD基因并与pMD18-T载体连接,经筛选得到重组质粒pMD-CD,进行酶切鉴定及测序。
2.提取pORF-HSVtk质粒,设计合适引物,通过PCR扩增出TK基因并与PMD18-T载体连接,经筛选得到重组质粒pMD-TK,进行酶切鉴定及测序。
3.将质粒pMD-CD进行双酶切,获得CD基因片段,连接与相同酶切的真核表达载体pEGFP-Su上,构建重组真核表达载体pEGS-CD,酶切鉴定。4.再将质粒pMD-TK进行双酶切,获得TK基因片段,连接与相同酶切的真核表达载体pEGS-CD上,构建重组真核表达载体pEGS-CD/TK,酶切鉴定。
结果
1.经酶切和测序证实成功获得CD基因(约1281bp),TK基因(约1161bp)。
2.经酶切鉴定成功构建重组质粒pEGS-CD。
3.经酶切鉴定成功构建重组质粒pEGS-CD/TK。
第三部分pEGS-CD/TK双自杀基因载体对胃癌SGC7901细胞的体外杀伤作用
目的
利用细胞转染技术,研究survivin启动子介导的CD/TK双自杀基因系统对胃癌细胞SGC7901的体外杀伤作用。
方法
1.利用脂质体转染技术,将pEGS-CD/TK双自杀基因质粒转染胃癌SGC7901细胞、GES-1细胞。
2. SGC790、GES-1细胞加入不同浓度的5-FC、GCV前体药物。MTT方法测定吸收值,计算细胞存活率。
3.转染和未转染pEGS-CD/TK的SGC7901细胞混合,加入5-FC+GCV二者混合液,观察有无旁观者效应。
4.应用RT-PCR检测转染细胞中CD、TK基因mRNA的表达；Western blot法检测转染细胞CD、TK蛋白的表达。
5.流式细胞术检测细胞凋亡率。
结果
1.在给予5-FC、GCV后并达到一定浓度时,5-FC和GCV对SGC7901细胞存活率随着药物浓度的升高而呈现下降趋势,其体外杀伤作用具有浓度依赖性,且联合用药对SGC7901细胞体外的杀伤作用要强于二者单独应用；而不同浓度梯度的5-FC和GCV对GES-1细胞的细胞存活率改变不大。
2.转染的SGC7901细胞即可引起大部分未转染的细胞发生凋亡,旁观者效应较为明显。
3.通过RT-PCR和(?) Western blot检测证实CD,TK基因在SGC7901细胞中成功表达。
4.转基因SGC7901细胞在给予前药处理24h后,治疗组SGC7901细胞凋亡率明显高于对照组凋亡率(P<0.01)。
第四部分pEGS-CD/TK双自杀基因系统对胃癌SGC7901细胞裸鼠模型的体内抑瘤效应
目的
观察survivin启动子介导的CD/TK双自杀基因系统对胃癌SGC7901细胞裸鼠模型的体内抑瘤效应。
方法
1.动物模型的建立：小鼠左腋下皮下接种2×106SGC7901细胞,第三天复种一次,建立胃癌动物模型。
2. SGC7901皮下移植术后第10天,实验分为4组,每组10支。分组方法：A组：注射重组pEGS-CD/TK与前药5-FC与GCV；B组：仅注射重组pEGS-CD/TK;C组：仅注射前药5-FC与GCV；D组：空白对照,不施加任何处理。每3天测量一次皮下移植瘤的大小,计算瘤体体积。处死裸小鼠,HE染色,观察肿瘤的病理变化。
3. RT-PCR检测(?)CD/TK基因的表达。
结果
1.接种肿瘤细胞后10天左右,出现皮下肿瘤结节。裸鼠成瘤达0.5cm后开始治疗。注射重组pEGS-CD/TK与前药5-FC与GCV组与仅注射pEGS-CD/TK,前药GCV和5-FC,空白对照组相比较,移植瘤体积明显缩小,有统计学意义(P<0.05)。
2.治疗组切片中可见肿瘤细胞数目稀少,胞浆少,细胞核较小且染色较深,细胞分裂相少,核和胞浆凝缩及坏死区散在分布,纤维血管较少,可见炎性细胞浸润
3.治疗组瘤体内RT-PCR可检测至(?)CD/TK基因表达
结论
1. Survivin启动子能在胃癌肿瘤细胞中特异表达。
2.经酶切和测序鉴定,利用分子克隆技术成功获得CD和TK基因。
3.成功构建重组Survivin启动子介导的CD/TK双自杀载体系统。
4.含CD和TK融合基因的双自杀基因载体对SGC7901细胞具有强烈的杀伤作用,并且存在明显的旁观者效应。治疗组SGC7901细胞凋亡率明显高于对照组凋亡率(P<0.01)。
5. RT-PCR及Western blot检测结果CD/TK基因在SGC7901细胞中成功表达。
6.应用SGC7901细胞可成功建立致瘤BALB/C裸小鼠。7. Survivin启动子介导的CD/TK双自杀基因能在胃癌小鼠的瘤体内特异表达。
8. Survivin启动子介导的CD/TK双自杀基因在前体药物GCV和5-FC作用下,能抑制胃癌瘤体的生长,具备体内抑瘤效应。
Gastric cancer is one of the most common digestive system malignancies in clinical practice. There are more than10million new cancers worldwide every year-Gastric cancer has become the first cause of death of all malignant tumors in some areas of China. In recent years, with the deepening of the stomach cancer research, the pathogenesis and treatment of gastric cancer have made a lot of achievements. However, the diagnosis and treatment of gastric cancer still faces many difficulties, and the overall treatment effect is still not ideal. The clinical characteristics shows "three low and one high", namely the diagnosis is low (about10%), surgical excision rate low (＜70%),5years of survival rate low (about40%), radical surgery relapse and metastasis rate high (about50%).Therefore, to find a new stomach cancer prevention and control method, will have a positive and important practical significance to further improve the overall prevention level and cure of gastric cancer.
Cancer gene therapy is usually transferring the exogenous genes into patients using expression vector and different methods, which produce the product to inhibit and kill cancer cells. Suicide gene therapy, also called gene-directed enzyme prodrug treatment, has become a new anti-tumor therapeutic approach after the traditional surgical resection, radiotherapy, chemical drug treatment.Suicide gene generally refers to the prodrug conversion gene or cytotoxic receptor gene from prokaryote or lower organisms (viruses and bacteria),which encode the specificity enzyme can convert the nontoxic prodrug (or cytotoxic factor) into toxic product (or cytotoxic factor) to achieve the purpose of killing cancer cells. At present, a variety of suicide genes have been found, including Escherichia coli cytosine deaminase (CD), herpes simplex virus-thymidine kinase (HSV-TK). Escherichia coli cytosine deaminase gene encodes the cytosine deaminase, which can convert the cytosine into uracil, change5-Fc into cells toxic metabolites5-Fu, to play cytotoxic effects through inhibiting RNA and DNA synthesis. HSV-TK gene encodes thymidine kinase, which can convert the nucleoside analogue (NA) into bisphosphate iodide, further turn into triphosphate compound to inhibit the DNA polymerases to play antitumor function.
In cancer gene therapy, one of key issues is to improve the targeting expression of therapeutic gene. The targeted expression, is to make the gene function as in tumor cells as possible, and to reduce the influence to normal cells. Specifically expressed promoter sequence in tumor cells has been widely used, which can drive the downstream gene to express in tumor cells specifically, is an effective way to solve the problems of tumor targeted gene therapy. At present, the embryo carcinoma antigen (CEA) promoter, telomerase gene promoter, etc have been used as the regulated element for tumor target gene therapy, but the promoters have some disadvantages, such as application is limited, regulation effect is weak. Survivin is a member of apoptosis inhibiting protein family, it express highly in most tumors, but do not express or lower express in adult normal terminal differentiation tissue, has the obvious tumour specific. Therefore, survivn specific promoter can be used to drive the gene express specific in the tumor cells, to avoid the damage to normal cells.
In the current study, we cloned the survivin promoter and constructed the CD/TK expression vector mediated by survivin promoter, then transfected into gastric cancers cells, established nude BALB/C mouse gastric cancers model, gave certain concentration of5-FC, GCV. We demonstrated that survivin-CD/TK systems have obvious target killing function to gastric cancer subcutaneous BALB/C rats.
Our studies include the following four parts.
Part I:Cloning of survivin promoter and express specific in the gastric cancer cell
Objective:
The aim of this study was to construct the recombinant EGFP expression vector driven by survivin promoter, and identify the promoter activity specific in gastric cancer cells.
Methods:
1. Human genome DNA was extracted from white blood cells. Primers were designed according to the sequence of survivin promoter. Survivin gene promoter was obtained by PCR technology, and ligated into the pMD18-T vector, followed by digestion with restriction endonuclease and sequencing.
2. pMD-survivin vector was digested by double restriction endonuclease to release the survivin fragment, and ligated into the pEGFP-C1vector to generate the recombinant pEGFP-Su, and then identified by enzyme digestion.
3. pEGFP-Su plasmid was transfected into gastric cancer SGC7901cells and normal gastric epithelial GES-1cell, and EGFP gene expression was detected by fluorescence microscope.
Results:
1. Human survivin promoter of910bp long was obtained via PCR method.
2. We constructed the recombinant pEGFP-Su plasmid successfully.
3. EGFP driven by survivin promoter can express specific in SGC7901gastric cancer cells, but not in the normal gastric epithelium GES-1cell.
Part II:Construction and identification of the recombinant pEGS-CD/TK double suicide genes vector
Objective:
To construct and identify the recombinant pEGS-CD/TK plasmid using molecular cloning technology
Methods:
1. E.coli BL21DNA was extracted. Primers were designed according to the sequence of CD gene. CD gene was obtained by PCR technology, and ligated into the pMD18-T vector, followed by digestion with restriction endonuclease and sequencing.
2. pORF-HSVtk was extracted and used as PCR template. Primers were designed according to the sequence of TK gene. TK gene was obtained by PCR technology, and ligated into the pMD18-T vector, followed by digestion with restriction endonuclease and sequencing.
3. pMD-CD vector was digested by double restriction endonuclease to release the CD gene fragment,and ligated into the pEGFP-Su vector to generate the recombinant pEGS-CD, then identified them by enzyme digestion.
4. pMD-TK vector was digested by double restriction endonuclease to release the TK gene fragment, and ligated into the pEGS-CD vector to generate the recombinant pEGS-CD/TK, then identified them by enzyme digestion.
Results:
1. CD gene (1281bp) and TK gene (1161bp) were obtained through PCR method.
2. We constructed the recombinant pEGS-CD plasmid successfully.
3. We constructed the recombinant pEGS-CD/TK plasmid successfully.
Part Ⅲ Killing effect of pEGS-CD/TK double suicide gene vector on the Gastric Cancer Cells in vitro
Objective:
To study the killing effect of CD/TK double suicide genes driven by survivin promoter on the gastric cancer cells in vitro.
Methods:
1. pEGS-CD/TK plasmid was transfected into SGC7901, GES-1cells using the liposome.
2. The prodrug5-FC and GCV were added into the SGC7901, GES-1cells, and then the cell survival rate was determined by MTT methods.
3. The untransfected and transfected SGC7901were mixed, followed by adding the prodrug5-FC, GCV. The bystander effect was observed through MTT methods.
4. CD, TK gene expression was detected by RT-PCR and Western blot.
5. Cell apoptosis rate was detected by flow cytometry.
Results:
1. SGC7901cell survival rate decreased with the concentration5-FC, GCV increased, and the killing effect in vitro showed concentration dependent.The killing effect of drug combination on SGC7901cells was stronger than the drug used alone in vitro. However, the5-FC and GCV had little effect on GES-1cells survival rate.
2. The transfected SGC7901cells can cause the untranfected cells apoptosis, showed the obvious bystander effect.
3. CD, TK gene can express in the transfected in the SGC7901cell through RT-PCR and Western blot assay.
4.The transfected SGC7901cells was treated by the prodrug for24h, SGC7901cell apoptosis rate of the treatment group was significantly higher than that of the control group (P<0.01).
Part IV:Killing effect of pEGS-CD/TK double suicide gene on the nude mice model of gastric cancer cells in vivo
Objective:
To investigate the killing effect of CD/TK double suicide genes on the nude mice model of gastric cancer cells in vivo.
Methods:
1. The nude mice were subcutaneously inoculated by5×106gastric cancer cells, re inoculated at the third day to establish the gastric cancer nude mice model.
2. After10days of SGC7901subcutaneous transplantation, the mice were divided into4groups (n=10). Group A:injected with recombinant pEGS-CD/TK and prodrug5-FC and GCV; Group B:only injected with recombinant pEGS-CD/TK; Group C:only injected prodrug5-FC and GCV; Group D:blank control, no any treatment. The size of the subcutaneous transplantation tumor was measured once every3days. The nude mice was killed and stained by HE method, the tumor pathological changes were observed.
3. CD/TK gene expression was detected by RT-PCR method.
Results:
1.Ten days after tumor cells inoculation, subcutaneous tumor nodules appeared.The treatment began after the nude mice tumor achieved0.5cm.Compared with the only injected pEGS-CD/TK, prodrug GCV and5-FC and blank control group, the transplantable tumor size in the injected with pEGS-CD/TK and prodrug GCV and5-FC group was sigficantly reduced, and showed statistically significant (P＜0.05).
2.Tumor cells number in the treatment group were visible scarce, had scant cytoplasm, nuclear was smaller and staining was deeper, the cell division was fewer, nuclear and cytoplasm condensed and necrotic area were scattered, fiber blood vessels were fewer, inflammatory cells infiltration was visible.
3. CD, TK gene expression could be detected by RT-PCR in the treatment group.
Conclusions
1. Survivin promoter expresses specific in the gastric cancer cells.
2. CD and TK genes have been obtained successfully by gene cloning technology.
3. CD/TK double suicide genes plasmid driven by survivin promoter has been constructed.
4. CD and TK double suicide genes have stronger killing effect on the SGC7901cells, and show the obvious bystander effect.SGC7901cell apoptosis rate of the treatment group is significantly higher than that of the control group (P＜0.01).
5. CD/TK gene express in SGC7901cells successfully.
6. Tumorigenic BALB/C nude mice have been successful established using SGC7901cells.
7. CD/TK double suicide gene driven by Survivin promoter can specifilly express in the gastric cancer cells.
8. CD/TK double suicide gene driven by survivin promoter can inhibit the growth of gastric cancer in the presence of prodrug drug GCV and5-FC, has an inhibitory effect in vivo.
引文
[1]Nettelbeck DM, Jerome V, Muller R.Gene therapy:designer promoters for tumour targeting [J].Trends Genet,2000,16:174-181.
[2]Willhauck MJ, Sharif Samani BR, Klutz K,et al.Alpha-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma[J]. Gene Ther,2008,15: 214-223.
[3]Qiu Y, Peng GL, Liu QC, et al. Selective killing of lung cancer cells using carcinoembryonic antigen promoter and double suicide genes, thymidine kinase and cytosine deaminase (pCEA-TK/CD) [J]. Cancer Lett,2012,316:31-38.
[4]Ma SH, Chen GG, Yip J,et al. Therapeutic effect of alpha-fetoprotein promoter-mediated tBid and chemotherapeutic agents on orthotopic liver tumor in mice[J].Gene Ther,2010, 17:905-912.
[5]Willhauck MJ, Sharif Samani BR, Klutz K, et al Alpha-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma[J]. Gene Ther,2008, 15:214-223.
[6]Kraaij R, van der Weel L, de Ridder CM, et al. A small chimeric promoter for high prostate-specific transgene expression from adenoviral vectors[J].2007,67:829-839.
[7]Gupta VK, Park JO, Kurihara T, et al. Selective gene expression using a DF3/MUC1 promoter in a human esophageal adenocarcinoma model[J].2003,10:206-212.
[8]Marconett CN, Sundar SN, Tseng M, et al. Indole-3-carbinol downregulation of telomerase gene expression requires the inhibition of estr ogen receptor-alpha and Spl transcription factor interactions within the hTERT promoter and mediates the Gl cell cycle arrest of human breast cancer cells [J].Carcinogenesis,2011,32:1315-323.
[9]Ambrosini G, Adida C, Altieri DC.A novel anti-apoptosis gene, survivin, expressed in cancer and rymphoma [J].Nat Med,1997,3:917-921.
[10]Bao R, Connolly DC, Murphy M, et al.Activation of cancer-specific gene expression by the survivin promoter [J]. J Natl Cancer Inst,2002,94:522-528.
[11]Adida C, Crotty PL, McGrath J, et al.Developmentally regulate d expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation [J]. Am J Pathol, 1998,152:43-49.
[12]Kim PJ, Plescia J, Clevers H, et al.Survivin and molecular pathogenesis of colorectal cancer[J].2003,362:205-209.
[13]Konno R, Yamakawa H, Utsunomiya H, et al.Expression of survivin and Bcl-2 in the normal human endometrium[J].Mol Hum Reprod,2000,6:529-534.
[14]袁成福黄秀凝程莉,等survivin启动子驱动的shRNA在宫颈癌SiHa细胞中的特异性表达[J].生物技术通报,2009,7：128-133.
[15]骆晓梅,张南征,刘家云,等survivin启动子的克隆及其在前列腺癌细胞系中的活性鉴 定[J].徐州医学院学报,2009,29：215-217.
[16]Altieri DC.Molecular cloning of effector cell protease receptor-1, a novel cell surface receptor for the protease factor Xa [J].J Biol Chem,1994,269:3139-3142.
[17]Wang TY, Wang L, Zhang JH,et al.A simplified universal genomic DNA extraction protocol suitable for PCR [J].Genet Mol Res,2011,10:519-525.
[18]Konno R, Yamakawa H, Utsunomiya H, et al.Expression of survivin and Bcl-2 in the normal human endometrium[J]. Mol Hum Reprod,2000,6:529-534.
[19]Li F, Altieri DC.Transcriptional analysis of human survivin gene expression [J]. Biochem J, 1999,2:305-311.
[20]Glaum MC, Wang Y, Raible DG, et al.Degranulation influences heparin-associated inhibition of RT-PCR in human lung mast cells [J].Clin Exp Allergy,2001,31:1631-1635.
[21]Don RH, Cox PT, Wainwright BJ et al,.'Touchdown'PCR to circumvent spurious priming during gene amplification [J]. Nucleic Acids Res,1991,19:4008.
[22]王天云张贵星薛乐勋.一种简便高效的改良降落PCR[J].中国生物工程杂志.2003,23：80-82.
[23]曾芳,卢银平,王凯平.人hepcidin真核表达载体的构建及稳定转染细胞系的建立[J].华中科技大学学报(医学版),2010,39(4)：524-527.
[24]骆江坤,方强,齐文娟,等.人白细胞介素23p19亚基基因的克隆和序列分析[J].蚌埠医学院学报,2010,35(6)：545-547.
[25]杨波,刘辉,吴亮亮,等.真核表达质粒pIRES-AcGFP-DNTβ Ⅱ的构建及其在COS-7细胞中的表达[J].现代肿瘤医学,2010,18(4)：643-646.
[26]Misteli T, Spector DL.Applications of the green fluorescent protein in cell biology and biotechnology[J].Nat Biotechnol,1997,15:961-964.
[27]Wang HG, Wang XF, Jing XY, et al.Effect of mutations in a simian virus 40 PolyA signal enhancer on green fluorescent protein reporter gene expression [J].Genet Mol Res,2011, 10:1866-883.
[28]Fan BS, Lou J Y.Enhancement of angiogenic effect of co-transfection human NGF and VEGF genes in rat bone marrow mesenchymal stem cells[J].Gene,2011,485:167-171.
[29]高歌,牛朝诗,董永飞,等EGFP-Cl-PEX真核表达载体的构建及其在大鼠骨髓间质干细胞中的表达[J].安徽医科大学学报,2008 43(3)：290-293.
[30]夏向文,李欣,冯敢生,等.双亚基共表达重组人白细胞介素12真核质粒pEGFP-Cl-IL-12的构建及表达[J].华中科技大学学报(医学版),2009 38(1)：83-86.
[31]薛丽香,童坦君,张宗玉.报告基因的选择及其研究趋向[J].生理科学进展,2002 33(4)：364-366.
[1]Trepel M, Stoneham CA, Eleftherohorinou H,et al.A heterotypic bystander effect for tumor cell killing after adeno-associated virus/phage-mediated, vascular-targeted suicide gene transfer[J].Mol Cancer Ther,2009,8:2383-2391.
[2]Bil J, Wlodarski P, Winiarska M, et al.Photodynamic therapy-driven induction of suicide cytosine deaminase gene[J]. Cancer Lett,2010,290:216-222.
[3]Preuss E, Muik A, Weber K, et al. Cancer suicide gene therapy with TK.007:superior killing efficiency and bystander effect[J].J Mol Med (Berl),2011,89:1113-1124.
[4]Amano S, Gu C, Koizumi S, et al. Tumoricidal bystander effect in the suicide gene therapy using mesenchymal stem cells does not injure normal brain tissues[J].Cancer Lett,2011, 306:99-105.
[5]Luo XR, Li JS, Niu Y, et al. Targeted killing effects of double CD and TK suicide genes controlled by survivin promoter on gastric cancer cell[J].Mol Biol Rep,2011,38:1201-1207.
[6]Wang X, Ji C, Ma D, et al. Antitumor effects of cytosine deaminase and thymidine kinase fusion suicide gene under the control of mdrl promoter in mdrl positive leukemia cells[J].Leuk Lymphoma,2007,48:1600-1609.
[7]Zhang Y, Wang CW, Wang ZG, et al.Construction of double suicide genes system controlled by MDR1 promoter with targeted expression in drug-resistant glioma cells[J].J Neurooncol,2008,86:3-11.
[8]Wu DH, Liu L, Chen LH.Antitumor effects and radiosensitization of cytosine deaminase and thymidine kinase fusion suicide gene on colorectal carcinoma cells[J].World J Gastroenterol,2005,11:3051-3055.
[9]Lee YJ, Lee H, Borrelli MJ.Gene.transfer into human prostate adenocarcinoma cells with an adenoviral vector:Hyperthermia enhances a double suicide gene expression, cytotoxicity and radiotoxicity[J].Cancer Gene Ther,2002,9:267-274.
[10]Adida C, Crotty PL, McGrath J, et al.Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation[J]. Am J Pathol, 1998,152:43-49.
[11]Kim PJ, Plescia J, Clevers H, et al. Survivin and molecular pathogenesis of colorectal cancer[J]. Lancet,2003,362:205-209.
[12]Konno R, Yamakawa H, Utsunomiya H, et al.Expression of survivin and Bcl-2 in the normal human endometrium[J].Mol Hum Reprod,2000,6:529-534.
[13]Austin EA, Huber BE.A first step in the development of gene therapy for colorectal carcinoma:cloning, sequencing, and expression of Escherichia coli cytosine deaminase[J]. 1993,43:380-387.
[14]McKnight SL.The nucleotide sequence and transcript map of the herpes simplex virus thymidine kinase gene [J].Nucleic Acids Res,1980,8:5949-5964.
[15]Mullen CA, Kilstrup M, Blaese RM. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivityto 5-fluorocytosine:a negative selection system. Proc Natl Acad Sci U S A,1992,89(1):33-337.
[16]Hamstra DA, Rice DJ, Fahmy S et al.,Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase[J].Hum Gene Ther,1999,10:1993-2003.
[17]Kucerova L, Matuskova M, Hlubinova K, et al.Bystander cytotoxicity in human medullary thyroid carcinoma cells mediated by fusion yeast cytosine deaminase and 5-fluorocytosine [J].Cancer Lett,2011,311(1):101-12.
[18]龚福生,郑秋红,谢云青,等.大肠杆菌胞嘧啶脱氨酶基因的克隆及其真核表达载体的构建[J].实用肿瘤杂志,2003,18(4)：268-270.
[19]Redaelli M, Franceschi V, Capocefalo A, et al.Herpes simplex virus type 1 thymidine kinase-armed bovine herpesvirus type 4-based vector displays enhanced oncolytic properties in immunocompetent orthotopic syngenic mouse and rat glioma models [J].Neuro Oncol,2012,6. [Epub ahead of print]
[20]Niess H, Bao Q, Conrad C, et al.Selective targeting of genetically engineered mesenchymal stem cells to tumor stroma microenvironments using tissue-specific suicide gene expression suppresses growth of hepatocellular carcinoma [J].Ann Surg,2011,254:767-774.
[21]Alekseenko Ⅳ, Kopantzev EP, Vinogradova TV,et al. Bicistronic vector for combined expression of the HSVtk killer gene and cytokine GM-CSF gene in cancer cells[J].Dokl Biochem Biophys,2011,439:174-177.
[22]Li S, Gao Y, Pu K et al.All-trans retinoic acid enhances bystander effect of suicide-gene therapy against medulloblastomas [J].Neurosci Lett,2011,503:115-119.
[23]Pu K, Li SY, Gao Y, et al.Bystander effect in suicide gene therapy using immortalized neural stem cells transduced with herpes simplex virus thymidine kinase gene on medulloblastoma regression [J].Brain Res,2011,1369:245-252.
[24]Cascante A, Huch M, Rodriguez LG, et al.Hum Gene Ther. Tat8-TK/GCV suicide gene therapy induces pancreatic tumor regression in vivo [J].2005,16:1377-1388.
[25]Cascante A, Abate-Daga D, Garcia-Rodriguez L, et al. GCV modulates the antitumoural efficacy of a replicative adenovirus expressing the Tat8-TK as a late gene in a pancreatic tumour model[J]. Gene Ther,2007,14:1471-1480.
[26]Beerens AM, Rots MG, Bermudez B, et al.Secretion of thymidine kinase to increase the effectivity of suicide gene therapy results in the loss of enzymatic activity [J]. J Drug Target,2008,16:26-35.
[1]Zhang C, Wang QT, Liu H, et al. Advancement and prospects of tumor gene therapy[J]. Chin J Cancer,2011,30:182-188.
[2]Yue QH, Hu XB, Yin Y, et al. Inhibition of prostate cancer by suicide gene targeting the FCY1 and HSV-TK genes[J]. Oncol Rep,2009,22:1341-1347.
[3]Martinez-Quintanilla J, Cascallo M, Gros A, et al. Positive selection of gene-modified cells increases the efficacy of pancreatic cancer suicide gene therapy[J]. Mol Cancer Ther,2009, 8:3098-3107.
[4]Kakinoki K, Nakamoto Y, Kagaya T, et al. Prevention of intrahepatic metastasis of liver cancer by suicide gene therapy and chemokine ligand 2/monocyte chemoattractant protein-1 delivery in mice[J]. J Gene Med,2010,12:1002-1013.
[5]Tang W, He Y, Zhou S, et al. A novel Bifidobacterium infantis-mediated TK/GCV suicide gene therapy system exhibits antitumor activity in a rat model of bladder cancer[J].J Exp Clin Cancer Res,2009,28:155.
[6]Qiu Y, Peng GL, Liu QC, et al. Selective killing of lung cancer cells using carcinoembryonic antigen promoter and double suicide genes, thymidine kinase and cytosine deaminase (pCEA-TK/CD) [J]. Cancer Lett,2012,316:31-38.
[7]Jia W, Mei L, Wang Y, et al. Double suicide genes selectively kill human umbilical vein endothelial cells[J]. Virol J,2011,8:74.
[8]黄宗海,李强,苏国强,等.KDR启动子驱动双白杀基因诱导胃癌细胞凋亡的体内实验研究[J].中国现代医学杂志,2007,17(1)：17-20.
[9]Christensen CL, Gjetting T, Poulsen TT, et al. Targeted cytosine deaminase-uracil phosphoribosyl transferase suicide gene therapy induces small cell lung cancer-specific cytotoxicity and tumor growth delay[J]. Clin Cancer Res,2010,16:2308-2319.
[10]Dachs GU, Tupper J, Tozer GM. From bench to bedside for gene-directed enzyme prodrug therapy of cancer[J]. Anticancer Drugs,2005,16:349-359.
[11]Li S, Gao Y, Pu K, et al. All-trans retinoic acid enhances bystander effect of suicide-gene therapy against medulloblastomas[J]. Neurosci Lett,2011,503:115-119.
[12]Kojima Y, Honda K, Hamada H, et al. Oncolytic gene therapy combined with double suicide genes for human bile duct cancer in nude mouse models[J]. J Surg Res,2009, 157:63-70.
[13]Xu B, Liu ZZ, Zhu GY, et al. Efficacy of recombinant adenovirus-mediated double suicide gene therapy in human keloid fibroblasts[J]. Clin Exp Dermatol,2008,33:322-328.
[14]Zhang Y, Wang CW, Wang ZG, et al. Construction of double suicide genes system controlled by MDR1 promoter with targeted expression in drug-resistant glioma cells[J]. J Neurooncol,2008,86:3-11.
[15]Desaknai S, Lumniczky K, Esik O, et al. Local tumour irradiation enhances the anti-tumour effect of a double-suicide gene therapy system in a murine glioma model[J]. J Gene Med, 2003,5:377-385.
[16]Bertin S, Neves S, Gavelli A, et al. Cellular and molecular events associated with the antitumor response induced by the cytosine deaminase/5-fluorocytosine suicide gene therapy system in a rat liver metastasis model[J]. Cancer Gene Ther,2007,14:858-866.
[17]Hu W, Liu W. Side populations of glioblastoma cells are less sensitive to HSV-TK/GCV suicide gene therapy system than the non-side population[J]. In Vitro Cell Dev Biol Anim, 2010,46:497-501.
[18]Engelmann C, Panis Y, Bolard J, et al. Liposomal encapsulation of ganciclovir enhances the efbcacy of herpessimplex Vims type 1 thymidine kinase suicide gene therapy against hepatic tumors in rats[J]. Human Gene Therapy,1999,10:1545-1551.
[19]Faneca H, Faustino A, Pedroso de Lima MC. Synergistic antitumoral effect of vinblastine and HSV-Tk/GCV gene therapy mediated by albumin-associated cationic liposomes[J]. J Control Release,2008,126:175-184.
[20]Pan JG, Zhou X, Luo R, et al. The adeno-associated virus-mediated HSV-TK/GCV suicide system:a potential strategy for the treatment of bladder carcinoma[J]. Med Oncol,2011.
[21]谭万龙,谢毅,吴元东,等.腺病毒介导融合双自杀基因治疗膀胱癌[J].南方医科大学学报,2006,26(5)：594-597.
[22]姚晓军,黄宗海,李强,等.CD／TK双自杀基因系统对Balb／c小鼠大肠癌的杀伤作用[J].实用医学杂志,2010,26(7)：1119-1122.
[23]张永红,唐罗生.双自杀基因CDTK载体系统对人视网膜母细胞瘤Y79细胞体外杀伤作用的研究[J].国际眼科杂志,2010,10(9)：1668-1671.
[24]孔恒,黄宗海,俞金龙,等.双自杀基因系统诱导乳腺癌细胞凋亡的体内外实验研究[J].中国现代医学杂志,2008,18(14)：1974-1978.
[25]Zhang P, Zeng H, Wei Q, et al. Improved effects of a double suicide gene system on prostate cancer cells by targeted regulation of prostate-specific membrane antigen promoter and enhancer[J].. Int J Urol,2008,15:442-448.
[26]胡铁山,李贵涛HSV-tk/GCV自杀基因系统对骨肉瘤细胞体外杀伤效应[J].第四军医大学学报,2004,25(3)：204-207.
[27]白志杰,黎玮,王亚轩,等.腺病毒介导的HSV-tk/GCV白杀基因系统靶向性治疗前列腺癌的实验研究[J].天津医科大学学报,2009,15(4)：689-691.
[28]Cottin S, Gould PV, Cantin L, et al. Gap junctions in human glioblastomas:implications for suicide gene therapy[J]. Cancer Gene Ther,2011,18:674-681.
[29]Matuskova M, Hlubinova K, Pastorakova A, et al. HSV-tk expressing mesenchymal stem cells exert bystander effect on human glioblastoma cells[J]. Cancer Lett,2010,290:58-67.
[30]Kuriyama S, Tsujinoue H, Yoshiji H. Immune response to suicide gene therapy[J]. Methods Mol Med,2004,90:353-369.
[31]Rzeszowska-Wolny J, Przybyszewski WM, et al. Ionizing radiation-induced bystander effects, potential targets for modulation of radiotherapy[J]. Eur J Pharmacol,2009, 625:156-164.
[1]Cunningham D, Allum WH, Stenning SP, et al.Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer[J]. N Engl J Med,2006,355(1):11-20.
[2]Tepper J, Krasna MJ, Niedzwiecki D, et al.Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer:CALGB 9781[J]. J Clin Oncol,2008,26(7):1086-92.
[3]Yamashita K, Sakuramoto S, Watanabe M.Genomic and epigenetic profiles of gastric cancer:potential diagnostic and therapeutic applications [J].Surg Today,2011,41(1):24-38.
[4]Guilford P, Humar B, Blair V.Hereditary diffuse gastric cancer:translation of CDH1 germline mutations into clinical practice [J].Gastric Cancer,2010,13(1):1-10
[5]Lupo-Stanghellini MT, Provasi E, Bondanza A, et al.Clinical impact of suicide gene therapy in allogeneic hematopoietic stem cell transplantation [J].Hum Gene Ther,2010, 21:241-50.
[6]Chen Y, Wang G, Kong D, et al.Double-targeted and double-enhanced suicide gene therapy mediated by generation 5 polyamidoamine dendrimers for prostate cancer [J].Mol Carcinog, 2011,1002/mc.21850.
[7]Qiu Y, Peng GL, Liu QC, et al.Selective killing of lung cancer cells using carcinoembryonic antigen promoter and double suicide genes, thymidine kinase and cytosine deaminase (pCEA-TK/CD) [JJ.Cancer Lett,2012,316(1):31-8.
[8]Nettelbeck DM, Jerome V, Miiller R.Gene therapy:designer promoters for tumour targeting[J].Trends Genet,2000,16(4):174-81.
[9]Reynolds PN, Nicklin SA, Kaliberova L, Boatman BG et al.Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo[J]. Nat Biotechnol,2001,19(9):838-42.
[10]Beck C, Uramoto H, Boren J, et al.Tissue-specific targeting for cardiovascular gene transfer. Potential vectors and future challenges [J]. Curr Gene Ther,2004,4(4):457-67.
[11]Xia K, Liang D, Tang A, et al. A novel fusion suicide gene yeast CDglyTK plays a role in radio-gene therapy of nasopharyngeal carcinoma[J]. Cancer Gene Ther,2004,11(12):790-796.
[12]孔恒,黄宗海,苏国强,等.KDR启动子驱动的双自杀基因抑制乳腺癌的体内实验研究[J].华中科技大学学报：医学版,2009,39(3)：327-30.
[13]Pantelouris EM.Absence of thymus in a mouse mutant[J].Nature,1968,217(5126):370-1.
[14]De Sousa MA, Parrott DM, Pantelouris EM.The lymphoid tissues in mice with congenital aplasia of the thymus[J].Clin Exp Immunol,1969,4(6):637-44.
[15]Pantelouris EM, Hair J.Thymus dysgenesis in nude (nu nu) mice[J].J Embryol Exp Morphol,1970,24(3):615-23.
[16]Rygaard J, Povlsen CO.Heterotransplantation of a human malignant tumour to "Nude" mice[J].Acta Pathol Microbiol Scand,1969,77(4):758-60.
[17]Rygaard J, Povsen CO. Heterotransplantation of a human malignant tumour to "nude" mice 1969 APMIS[J].2007,115(5):604-6.
[18]Gallie BL, Albert DM, Wong JJ, et al. Heterotransplantation of retinoblastoma into the athymic "nude" mouse[J].Invest Ophthalmol Vis Sci,1977,16(3):256-9.
[19]Giovanella BC, Fogh J.The nude mouse in cancer research[J].Adv Cancer Res,1985, 44:69-120.
[20]Sharkey FE, Fogh J.Considerations in the use of nude mice for cancer research[J].Cancer Metastasis Rev,1984,3(4):341-60.
[21]Fogh J, Fogh JM, Orfeo T.One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice[J].J Natl Cancer Inst.1977 Jul;59(1):221-6.
[22]Li Y, Li B, Xiang CP, et al.Characterization of gastric cancer models from different cell lines orthotopically constructed using improved implantation techniques[J].World J Gastroenterol.2012,18(2):136-43.
[23]Follet J, Remy L, Hesry V, et al.Adaptation to statins restricts human tumour growth in Nude mice[J].BMC Cancer,2011,11:491.
[24]Sumida T, Kitadai Y, Shinagawa K, et al.Anti-stromal therapy with imatinib inhibits growth and metastasis of gastric carcinoma in an orthotopic nude mouse model[J].Int J Cancer. 2011 May 1;128(9):2050-62.
[25]Zhao G, Guo LL, Xu JY, et al.Integrin-linked kinase in gastric cancer cell attachment, invasion and tumor growth [J]. World J Gastroenterol,2011,17(30):3487-96.
[26]Li J, Mo ML, Chen Z, Yang J, et al.HSulf-1 inhibits cell proliferation and invasion in human gastric cancer[J].Cancer Sci,2011,102(10):1815-21.
[27]Cui Y, Urschel JD, Petrelli NJ. Effect of pyloric drainage on the healing of esophagogastric anastomoses in rats. Can J Surg,2000,43(6):456-458.
[28]张永红,,唐罗生.双自杀基因CDTK载体系统对裸小鼠Y79细胞皮下移植瘤的杀伤作用[J].国际眼科杂志,2010,10(10)：1871-1873.
[29]Chen Y, Wang G, Kong D, et al.Double-targeted and double-enhanced suicide gene therapy mediated by generation 5 polyamidoamine dendrimers for prostate cancer[J].Mol Carcinog 2011.10.1002/mc.21850
[30]Qiu Y, Peng GL, Liu QC, et al.Selective killing of lung cancer cells using carcinoembryonic antigen promoter and double suicide genes, thymidine kinase and cytosine deaminase (pCEA-TK/CD) [J].Cancer Lett,2012,316:31-38.
[1]Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics,2002[J].CA Cancer J Clin, 2005,55:74-108.
[2]Roesomando AJ, Sanghera JS, Marsden LA, et al.Biochemical characterization of a family of scrine/threonine protein kinascs regulated by tyrosine and scrine/threonine phosphorylations [J] J Biol Chem,1991,266:20270-20275.
[3]Shah MA, Schwartz GK.Treatment of metastatic esophagus and gastric cancer [J].Semin Oncol,2004,31:574-587.
[4]Bornschein J, Rokkas T, Selgrad M, et al. Gastric cancer:clinical aspects, epidemiology and molecular background [J].Helicobacter,2011,1:45-52.
[5]Vogiatzi P, Vindigni C, Roviello F, et a 1.Deciphering the underlying genetic and epigenetic events leading to gastric carcinogenesis[J]. J Cell Physiol,2007,211:287-295.
[6]Crew KD, Neugut Al. Epidemiology of gastric cancer [J]. World J Gastroenterol 2006, 12:354-362.
[7]Shikata K, Doy Y, Yonemoto K, et al. Population-based prospective study of the combined influence of cigarette smoking and Helicobacter pylori infection on gastric cancer incidence:the Hisayama study[J]. Am J Epidemiol,2008,12:1409-1415.
[8]Fan H, Liu D, Qiu X, et al. A functional polymorphism in the DNA methyltransferase-3A promoter modifies the susceptibility in gastric cancer but not in esophageal carcinoma[J]. BMC Med,2010,8:12.
[9]Samuel MS, Suzuki H, Buchert M, et al. Elevated Dnmt3a activity promotes polyposis in Ape Min mice by relaxing extracellular restrains on Wnt signaling[J]. Gastroenterology, 2009; 137:902-13.
[10]Ding WJ, Fang JY, Chen XY, et al. The expression and clinical significance of DNA methyltransferase proteins in human gastric cancer[J]. Dig Dis Sci,2008,53:2083-2089.
[11]Ju H, Lim B, Kim M, et al. A regulatory polymorphism at position-309 in PTPRCAP is associated with susceptibility to diffuse-type gastric cancer and gene expression[J]. Neoplasia,2009,11:1340-1347.
[12]Motoya S, Kitamura K, Matsuda A, et al.Interaction between CD45-AP and protein-tyrosine kinases involved in T cell receptor signaling[J]. J Biol Chem,1999,274: 14392-14399.
[13]Avizienyte E, Wyke AW, Jones RJ, et al. SRC-induced de-regulation of E-cadherin in colon cancer cells requires integrin signaling[J]. Nat Cell Biol,2002,4:632-638.
[14]Sakamoto H, Yoshimura K, Saeki N, et al. Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer[J]. Nat Genet,2008,40:730-740.
[15]Lu Y, Chen J, Ding Y, et al. Genetic variation of PSCA gene is associated with the risk of both diffuse and intestinal-type gastric cancer in a Chinese population[J]. Int J Cancer, 2010;127:2183-9.
[16]Ke Q, Liang J, Wang LN, et al. Potentially functional polymorphisms of the vascular endothelial growth factor gene and risk of gastric cancer[J]. Mol Carcinog,2008,47:647-651.
[17]Zhao R, Liu XQ, Wu XP, et al. Vascular endothelial growth factor (VEGF) enhances gastric carcinoma invasiveness via integrin alpha (v) beta6[J]. Cancer Lett,2010,287:150-156.
[18]Guan X, Zhao H, Niu J, Tang D, Ajani JA, Wei Q. The VEGF-634G＞C promoter polymorphism is associated with risk of gastric cancer[J]. BMC Gastroenterol,2009,9:77.
[19]Tahara T, Shibata T, Nakamura M, et al. Effect of polymorphisms in the 3(?) untranslated region (3(?)-UTR) of vascular endothelial growth factor gene on gastric cancer and peptic ulcer diseases in Japan[J]. Mol Carcinog,2009,48:1030-1037.
[20]Caldecott KW, Tucker JD, Stanker LH, Thompson LH. Characterization of the XRCC1-DNA ligase III complex in vitro and its absence from mutant hamster cells [J]. Nucleic Acids Res,1995,23:4836-4843.
[21]Hao B, Miao X, Li Y, et al. A novel T-77C polymorphism in DNA repair gene XRCC1 contributes to diminished promoter activity and increased risk of non-small cell lung cancer[J].Oncogene,2006,25:3613-3620.
[22]Corso G, Marrelli D, Pedrazzani C, et al. Gastric cardia carcinoma is associated with the promoter-77T>C gene polymorphism of X-ray cross-complementing group 1 (XRCC1) [J].J Gastrointest Surg,2009,13:2233-2238.
[23]Ross JS, McKenna BJ. The HER-2/neu oncogene in tumours of the gastrointestinal tract[J]. Cancer Invest,2001,19:554-568.
[24]Kozma L, Kiss I, Hajdu J, et al.C-myc amplification and cluster analysis in human gastric carcinoma[J].Anticancer Res,2001,21:707-710.
[25]Pan G, Lv Hui, Ren H, et al. Elevated expression of semaphoring 5A in human gastric cancer and its implication in carcinogenesis[J].Life Sci,2010;86:139-44.
[26]Florou D, Papadopoulos IN, Scorilas A. Molecular analysis and prognostic impact of the novel apoptotic gene BCL2L12 in gastric cancer[J]. Biochem Biophys Res Commun, 2010,391:214-218.
[27]Berger SL. The complex language of chromatin regulation during transcription[J]. Nature, 2007,447:407-412.
[28]Zeng J, Ge Z, Wang L, et al. The histone demethylase RBP2 is overexpressed in gastric cancer and its inhibition triggers senescence of cancer cells[J]. Gastroenterology,2010,138: 981-992.
[29]Vogiatzi P, Vindigni C, Roviello F, et al. Deciphering the underlying genetic and epigenetic events leading to gastric carcinogenesis[J]. J Cell Physiol,2007,211:287-295.
[30]Crew KD, Neugut Al. Epidemiology of gastric cancer[J]. World J Gastroenterol,2006,12: 354-362.
[31]Pinheiro H, Bordeira-Carric,o R, Seixas S, et al. Allele-specific CDH1 downregulation and hereditary diffuse gastric cancer[J].Hum Mol Genet,2010,5:943-952.
[32]Dohi O, Takada H, Wakabayashi N, et al. Epigenetic silencing of RELN in gastric cancer[J]. Int J Oncol,2010,36:85-92.
[33]Du P, Ye HR, Gao J, et al. Methylation of PTCH1a gene in a subset of gastric cancers[J]. World J Gastroenterol,2009,15:3799-3806.
[34]Ye Q, Shen Y, Wang X, et al. Hypermethylation of HLC class Ⅰ is associated with HLA class Ⅰ down-regulation in human gastric cancer[J]. Tissue Antigens,2010,75:30-39.
[35]Agarwal R, Mori Y, Cheng Y, et al. Silencing of claudin-11 is associated with increased invasiveness of gastric cancer cells[J].PLoS ONE,2009,4:8002.
[36]Zhao C, Bu X, Zhang N, et al. Downregulation of SFRP5 expression and its inverse correlation with those of MMP-7 and MTI-MMP in gastric cancer [J]. BMC Cancer, 2009,9:224.
[37]Rhyu MG, Park WS, Meltzer SJ. Microssatelite instability occurs frequently in human gastric carcinoma[J]. Oncogene,1994,1:29-32.
[38]Carneiro F, Oliveira C, Leite M, Seruca R. Molecular targets and biological modifiers in gastric cancer[J]. Semin Diagn Pathol,2008,4:274-287.
[39]Velho S, Oliveira C, Paredes J, et al. Mixed lineage kinase 3gene mutations in mismatch repair deficient gastrointestinal tumours [J]. Hum Mol Genet,2010,19:697-706.
[40]Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, Karson EM, Lotze MT, Yang JC, Topalian SL, et al. Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction[J]. N Engl J Med,1990,323(9):570-578.
[41]Freeman SM, Abboud CN, Whartenby KA, et al. The "bystander effect":tumor regression when a fraction of the tumor mass is genetically modified [J]. Cancer Res,1993,53: 5274-5283.
[42]Matono S, Tanaka T, Sueyoshi S,et al.Bystander effect in suicide gene therapy is directly proportional to the degree of gap junctional intercellular communication in esophageal cancer[J].Int J Oncol,2003,23:1309-1315.
[43]Oshiro TM, Enobe CS,Ara jo CA,et al.PAS-1,a protein affinitypurified from Ascafis suunl worms,maintains the ability to modulate the immune response to a bystander antigen[J]. Immunol Cell Biol,2006,84:138-144.
[44]Kimm M,Sami L,Esko A,et al.Evaluation of herp es simplex thymidine kinase mediated gene therapy in experimental pancreatic cancer[J].J Gene,2000,2:361-367.
[45]Pan X,Li ZS,Xu GM,et al.Adenovirus-mediated gene transfer in the treatment of pancrealic cancer[J].Pancreas,2003,26:274-278.
[46]Puhlmann M.Gnant M,Brown CK,et al.Thymidine kinase deleted vaccinia virus expressing pufine nucleeside phosphorylase as a vector for tumor directed gene therapy[J]. Hum Gene Ther,1999,10:649-657.
[47]Tahara E, Semba S, Tahara H. Molecular biological observations in gastric cancer[J]. Semin Oncol,1996,23:307-315.
[48]Baker SJ, Markowitz S, Fearon ER, et al.Vogelstein B.Suppression of human colorectal carcinoma cell growth by wildtype p53[J]. Science,1990,249:912-915.
[49]Mercer WE, Shields MT, Amin M, et al. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53[J]. Proc Natl Acad Sci USA,1990,87:6166-6170.
[50]Matozaki T, Sakamoto C, Suzuki T, et al. p53 gene mutations in human gastric cancer: wild-type p53 but not mutant p53 suppresses growth of human gastric cancer cells[J]. Cancer Res,1992,52:4335-4341.
[51]Ohashi M, Kanai F, Ueno H, et al. Adenovirus mediated p53 tumour suppressor gene therapy for human gastric cancer cells in vitro and in vivo[J]. Gut,1999,44:366-371
[52]Tamura GAlterations of tumor suppressor and tumor-related genes in the development and progression of gastric cancer [J].World J Gastroenterol,2006,12:192-198.
[53]Chaudhary KS, Abel PD, Stamp GWH, Lalani EN. Differential expression of cell death regulators in response to thapsigargin and adriamycin in Bcl-2 transfected DU145 prostatic cancer cells. J Pathol,2001,193:522-529.
[54]Jeong Yw,Kim KS,Oh JY,et al.Exogenous wild type p16INK4A gene induces delayed cell proliferation and promotes chemosensitivity through decreased pRB and increased E2F-1 expressions[J].Int J Mol Med,2003;12:61-65.
[55]Guo C,Ding J,Yao I,el al.Tumor suppressor gene Runx3 sensitizes gastric cancer cells to chemotherapeutic drugs by downregulating Bcl-2,MDR-I and MRP-1[J].Int J Cancer,2005, 116:155-160.
[56]Sun HW, Tong SL, He J, et al. RhoA and RhoC-siRNA inhibit the proliferation and invasiveness activity of human gastric carcinoma by Rho/PI3K/Akt pathway. World J Gastroenterrol,2007,13:3517-3522.
[57]Ueda M, Kokura S, Imamoto E, et al. Blocking of NF-B activation enhances the tumor necrosis factorkB-induced apoptosisof a human gastric cancer cell line. Cancer Lett,2003, 193:177-182.
[58]Hang Y, Zheng YC, Cao Y, et al. Suppression of gastric cancer growth by adenovirus-mediated transfer of the PTEN gene.World J Gastroenterol,2005,11:2224-2229.
[59]Tu SP, Jiang XH, Lin MCM, et al. Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer.Cancer Res,2003,63:7724-7732
[60]Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature,1996,383:787-793.
[61]Kosaka K,Yashiro M,Sakate Y,et al.CD80 gene therapy for lymph node involvement by gastric carcinoma[J].Int J Oncol,2004,25:1319-1325.
[62]Tanaka H,Yashiro M.Sunami T.et al.Lipid-mediated genetransfeetion of intercelular adhesion molecule suppresses the peritoneal metastasis of gastric carcinoma[J].Im J Mol Med,2002,10:613.
[63]Kircheis R,Kupcu Z,Wallner G,et al.Cytokine gene-modified tumor cells for prophylactic and therapeutic vaccination:IL-2, IFN-gamma,or combination IL-2+IFN-gamma[J]. Cytokines Cell Mol Ther,1998,4:95-103.
[64]Motoi F,Sunamura M,Ding L,et a 1.Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication competent adenovirus[J].Hum Gene Ther, 2000,11:223-235.
[65]Wu J, Shi YQ, Wu KC, et al. Angiostatin up-regulation in gastric cancer cell SGC7901 inhibits tumorigenesis in nude mice. World J Gastroenterol,2003,9:59-64.
[66]Nie MM, Fang GE, Wang XH, et al.Anti-tumor effect of gene-viral therapeutic system CNHK300-murine endostatin on nude mouse gastric cancer. Zhonghua Wei Chang Wai Ke Za Zhi,2007,10:565-569.
[67]Fujiuchi S, Yamazaki Y, Fujita Y, et al. S-nitrosoglutathione (SNOG) accumulates hypoxia inducible factor-1 alpha in main pulmonary artery endothelial cells but not in micro pulmonary vessel endothelial cells. Adv Exp Med Biol,2006,580:63-71.
[68]Kim R, Minami K, Nishimoto N, Toge T. Enhancement of antitumor effect by intratumoral administration of bax gene in combination with anticancer drugs in gastric cancer. Int J Oncol,2001; 18:363-367.
[69]Khare PD, Shao-Xi L, Kuroki M, et al. Specifically targeted killing of carcinoembryonic antigen (CEA)-expressing cells by a retroviral vector displaying single-chain variable fragmented antibody to CEA and carrying the gene for inducible nitric oxide synthase[J]. Cancer Res 2001;61:370-375.
[70]Tanaka T, Huang J, Hirai S, et al. Carcinoembryonic antigentargeted selective gene therapy for gastric cancer through FZ33 fiber-modified adenovirus vectors [J]. Clin Cancer Res, 2006,12:3803-3813.
[71]Heideman DAM, Snijders PJF, Craanen ME, et al. Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors [J]. Cancer Gene Ther,2001,8:342-351.
[72]Williams C, Shattuck-Brandt RL, DuBois RN. The role of COX-2 in intestinal cancer[J]. Ann N Y Acad Sci,1999,889:72-83.
[73]Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M.Expression of cyclooxygenase-2 in human gastric carcinoma[J]. Cancer Res,1997,57:1276-1280.
[74]Yamamoto M, Alemany R, Adachi Y, Grizzle WE, Curiel DT.Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers[J]. Mol Ther,2001,3:385-394.
[75]Luo XR, Li JS, Niu Y, Miao LTargeted killing effects of double CD and TK s uicide genes controlled by survivin promoter on gastric cancer cell[J]. Mol Biol Rep,2011,38(2): 1201-1207.
[2]Willhauck MJ, Sharif Samani BR, Klutz K,et al.Alpha-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma[J]. Gene Ther,2008,15: 214-223.
[3]Qiu Y, Peng GL, Liu QC, et al. Selective killing of lung cancer cells using carcinoembryonic antigen promoter and double suicide genes, thymidine kinase and cytosine deaminase (pCEA-TK/CD) [J]. Cancer Lett,2012,316:31-38.
[4]Ma SH, Chen GG, Yip J,et al. Therapeutic effect of alpha-fetoprotein promoter-mediated tBid and chemotherapeutic agents on orthotopic liver tumor in mice[J].Gene Ther,2010, 17:905-912.
[5]Willhauck MJ, Sharif Samani BR, Klutz K, et al Alpha-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma[J]. Gene Ther,2008, 15:214-223.
[6]Kraaij R, van der Weel L, de Ridder CM, et al. A small chimeric promoter for high prostate-specific transgene expression from adenoviral vectors[J].2007,67:829-839.
[7]Gupta VK, Park JO, Kurihara T, et al. Selective gene expression using a DF3/MUC1 promoter in a human esophageal adenocarcinoma model[J].2003,10:206-212.
[8]Marconett CN, Sundar SN, Tseng M, et al. Indole-3-carbinol downregulation of telomerase gene expression requires the inhibition of estr ogen receptor-alpha and Spl transcription factor interactions within the hTERT promoter and mediates the Gl cell cycle arrest of human breast cancer cells [J].Carcinogenesis,2011,32:1315-323.
[9]Ambrosini G, Adida C, Altieri DC.A novel anti-apoptosis gene, survivin, expressed in cancer and rymphoma [J].Nat Med,1997,3:917-921.
[10]Bao R, Connolly DC, Murphy M, et al.Activation of cancer-specific gene expression by the survivin promoter [J]. J Natl Cancer Inst,2002,94:522-528.
[11]Adida C, Crotty PL, McGrath J, et al.Developmentally regulate d expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation [J]. Am J Pathol, 1998,152:43-49.
[12]Kim PJ, Plescia J, Clevers H, et al.Survivin and molecular pathogenesis of colorectal cancer[J].2003,362:205-209.
[13]Konno R, Yamakawa H, Utsunomiya H, et al.Expression of survivin and Bcl-2 in the normal human endometrium[J].Mol Hum Reprod,2000,6:529-534.
[14]袁成福黄秀凝程莉,等survivin启动子驱动的shRNA在宫颈癌SiHa细胞中的特异性表达[J].生物技术通报,2009,7：128-133.
[15]骆晓梅,张南征,刘家云,等survivin启动子的克隆及其在前列腺癌细胞系中的活性鉴 定[J].徐州医学院学报,2009,29：215-217.
[16]Altieri DC.Molecular cloning of effector cell protease receptor-1, a novel cell surface receptor for the protease factor Xa [J].J Biol Chem,1994,269:3139-3142.
[17]Wang TY, Wang L, Zhang JH,et al.A simplified universal genomic DNA extraction protocol suitable for PCR [J].Genet Mol Res,2011,10:519-525.
[18]Konno R, Yamakawa H, Utsunomiya H, et al.Expression of survivin and Bcl-2 in the normal human endometrium[J]. Mol Hum Reprod,2000,6:529-534.
[19]Li F, Altieri DC.Transcriptional analysis of human survivin gene expression [J]. Biochem J, 1999,2:305-311.
[20]Glaum MC, Wang Y, Raible DG, et al.Degranulation influences heparin-associated inhibition of RT-PCR in human lung mast cells [J].Clin Exp Allergy,2001,31:1631-1635.
[21]Don RH, Cox PT, Wainwright BJ et al,.'Touchdown'PCR to circumvent spurious priming during gene amplification [J]. Nucleic Acids Res,1991,19:4008.
[22]王天云张贵星薛乐勋.一种简便高效的改良降落PCR[J].中国生物工程杂志.2003,23：80-82.
[23]曾芳,卢银平,王凯平.人hepcidin真核表达载体的构建及稳定转染细胞系的建立[J].华中科技大学学报(医学版),2010,39(4)：524-527.
[24]骆江坤,方强,齐文娟,等.人白细胞介素23p19亚基基因的克隆和序列分析[J].蚌埠医学院学报,2010,35(6)：545-547.
[25]杨波,刘辉,吴亮亮,等.真核表达质粒pIRES-AcGFP-DNTβ Ⅱ的构建及其在COS-7细胞中的表达[J].现代肿瘤医学,2010,18(4)：643-646.
[26]Misteli T, Spector DL.Applications of the green fluorescent protein in cell biology and biotechnology[J].Nat Biotechnol,1997,15:961-964.
[27]Wang HG, Wang XF, Jing XY, et al.Effect of mutations in a simian virus 40 PolyA signal enhancer on green fluorescent protein reporter gene expression [J].Genet Mol Res,2011, 10:1866-883.
[28]Fan BS, Lou J Y.Enhancement of angiogenic effect of co-transfection human NGF and VEGF genes in rat bone marrow mesenchymal stem cells[J].Gene,2011,485:167-171.
[29]高歌,牛朝诗,董永飞,等EGFP-Cl-PEX真核表达载体的构建及其在大鼠骨髓间质干细胞中的表达[J].安徽医科大学学报,2008 43(3)：290-293.
[30]夏向文,李欣,冯敢生,等.双亚基共表达重组人白细胞介素12真核质粒pEGFP-Cl-IL-12的构建及表达[J].华中科技大学学报(医学版),2009 38(1)：83-86.
[31]薛丽香,童坦君,张宗玉.报告基因的选择及其研究趋向[J].生理科学进展,2002 33(4)：364-366.
[1]Trepel M, Stoneham CA, Eleftherohorinou H,et al.A heterotypic bystander effect for tumor cell killing after adeno-associated virus/phage-mediated, vascular-targeted suicide gene transfer[J].Mol Cancer Ther,2009,8:2383-2391.
[2]Bil J, Wlodarski P, Winiarska M, et al.Photodynamic therapy-driven induction of suicide cytosine deaminase gene[J]. Cancer Lett,2010,290:216-222.
[3]Preuss E, Muik A, Weber K, et al. Cancer suicide gene therapy with TK.007:superior killing efficiency and bystander effect[J].J Mol Med (Berl),2011,89:1113-1124.
[4]Amano S, Gu C, Koizumi S, et al. Tumoricidal bystander effect in the suicide gene therapy using mesenchymal stem cells does not injure normal brain tissues[J].Cancer Lett,2011, 306:99-105.
[5]Luo XR, Li JS, Niu Y, et al. Targeted killing effects of double CD and TK suicide genes controlled by survivin promoter on gastric cancer cell[J].Mol Biol Rep,2011,38:1201-1207.
[6]Wang X, Ji C, Ma D, et al. Antitumor effects of cytosine deaminase and thymidine kinase fusion suicide gene under the control of mdrl promoter in mdrl positive leukemia cells[J].Leuk Lymphoma,2007,48:1600-1609.
[7]Zhang Y, Wang CW, Wang ZG, et al.Construction of double suicide genes system controlled by MDR1 promoter with targeted expression in drug-resistant glioma cells[J].J Neurooncol,2008,86:3-11.
[8]Wu DH, Liu L, Chen LH.Antitumor effects and radiosensitization of cytosine deaminase and thymidine kinase fusion suicide gene on colorectal carcinoma cells[J].World J Gastroenterol,2005,11:3051-3055.
[9]Lee YJ, Lee H, Borrelli MJ.Gene.transfer into human prostate adenocarcinoma cells with an adenoviral vector:Hyperthermia enhances a double suicide gene expression, cytotoxicity and radiotoxicity[J].Cancer Gene Ther,2002,9:267-274.
[10]Adida C, Crotty PL, McGrath J, et al.Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation[J]. Am J Pathol, 1998,152:43-49.
[11]Kim PJ, Plescia J, Clevers H, et al. Survivin and molecular pathogenesis of colorectal cancer[J]. Lancet,2003,362:205-209.
[12]Konno R, Yamakawa H, Utsunomiya H, et al.Expression of survivin and Bcl-2 in the normal human endometrium[J].Mol Hum Reprod,2000,6:529-534.
[13]Austin EA, Huber BE.A first step in the development of gene therapy for colorectal carcinoma:cloning, sequencing, and expression of Escherichia coli cytosine deaminase[J]. 1993,43:380-387.
[14]McKnight SL.The nucleotide sequence and transcript map of the herpes simplex virus thymidine kinase gene [J].Nucleic Acids Res,1980,8:5949-5964.
[15]Mullen CA, Kilstrup M, Blaese RM. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivityto 5-fluorocytosine:a negative selection system. Proc Natl Acad Sci U S A,1992,89(1):33-337.
[16]Hamstra DA, Rice DJ, Fahmy S et al.,Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase[J].Hum Gene Ther,1999,10:1993-2003.
[17]Kucerova L, Matuskova M, Hlubinova K, et al.Bystander cytotoxicity in human medullary thyroid carcinoma cells mediated by fusion yeast cytosine deaminase and 5-fluorocytosine [J].Cancer Lett,2011,311(1):101-12.
[18]龚福生,郑秋红,谢云青,等.大肠杆菌胞嘧啶脱氨酶基因的克隆及其真核表达载体的构建[J].实用肿瘤杂志,2003,18(4)：268-270.
[19]Redaelli M, Franceschi V, Capocefalo A, et al.Herpes simplex virus type 1 thymidine kinase-armed bovine herpesvirus type 4-based vector displays enhanced oncolytic properties in immunocompetent orthotopic syngenic mouse and rat glioma models [J].Neuro Oncol,2012,6. [Epub ahead of print]
[20]Niess H, Bao Q, Conrad C, et al.Selective targeting of genetically engineered mesenchymal stem cells to tumor stroma microenvironments using tissue-specific suicide gene expression suppresses growth of hepatocellular carcinoma [J].Ann Surg,2011,254:767-774.
[21]Alekseenko Ⅳ, Kopantzev EP, Vinogradova TV,et al. Bicistronic vector for combined expression of the HSVtk killer gene and cytokine GM-CSF gene in cancer cells[J].Dokl Biochem Biophys,2011,439:174-177.
[22]Li S, Gao Y, Pu K et al.All-trans retinoic acid enhances bystander effect of suicide-gene therapy against medulloblastomas [J].Neurosci Lett,2011,503:115-119.
[23]Pu K, Li SY, Gao Y, et al.Bystander effect in suicide gene therapy using immortalized neural stem cells transduced with herpes simplex virus thymidine kinase gene on medulloblastoma regression [J].Brain Res,2011,1369:245-252.
[24]Cascante A, Huch M, Rodriguez LG, et al.Hum Gene Ther. Tat8-TK/GCV suicide gene therapy induces pancreatic tumor regression in vivo [J].2005,16:1377-1388.
[25]Cascante A, Abate-Daga D, Garcia-Rodriguez L, et al. GCV modulates the antitumoural efficacy of a replicative adenovirus expressing the Tat8-TK as a late gene in a pancreatic tumour model[J]. Gene Ther,2007,14:1471-1480.
[26]Beerens AM, Rots MG, Bermudez B, et al.Secretion of thymidine kinase to increase the effectivity of suicide gene therapy results in the loss of enzymatic activity [J]. J Drug Target,2008,16:26-35.
[1]Zhang C, Wang QT, Liu H, et al. Advancement and prospects of tumor gene therapy[J]. Chin J Cancer,2011,30:182-188.
[2]Yue QH, Hu XB, Yin Y, et al. Inhibition of prostate cancer by suicide gene targeting the FCY1 and HSV-TK genes[J]. Oncol Rep,2009,22:1341-1347.
[3]Martinez-Quintanilla J, Cascallo M, Gros A, et al. Positive selection of gene-modified cells increases the efficacy of pancreatic cancer suicide gene therapy[J]. Mol Cancer Ther,2009, 8:3098-3107.
[4]Kakinoki K, Nakamoto Y, Kagaya T, et al. Prevention of intrahepatic metastasis of liver cancer by suicide gene therapy and chemokine ligand 2/monocyte chemoattractant protein-1 delivery in mice[J]. J Gene Med,2010,12:1002-1013.
[5]Tang W, He Y, Zhou S, et al. A novel Bifidobacterium infantis-mediated TK/GCV suicide gene therapy system exhibits antitumor activity in a rat model of bladder cancer[J].J Exp Clin Cancer Res,2009,28:155.
[6]Qiu Y, Peng GL, Liu QC, et al. Selective killing of lung cancer cells using carcinoembryonic antigen promoter and double suicide genes, thymidine kinase and cytosine deaminase (pCEA-TK/CD) [J]. Cancer Lett,2012,316:31-38.
[7]Jia W, Mei L, Wang Y, et al. Double suicide genes selectively kill human umbilical vein endothelial cells[J]. Virol J,2011,8:74.
[8]黄宗海,李强,苏国强,等.KDR启动子驱动双白杀基因诱导胃癌细胞凋亡的体内实验研究[J].中国现代医学杂志,2007,17(1)：17-20.
[9]Christensen CL, Gjetting T, Poulsen TT, et al. Targeted cytosine deaminase-uracil phosphoribosyl transferase suicide gene therapy induces small cell lung cancer-specific cytotoxicity and tumor growth delay[J]. Clin Cancer Res,2010,16:2308-2319.
[10]Dachs GU, Tupper J, Tozer GM. From bench to bedside for gene-directed enzyme prodrug therapy of cancer[J]. Anticancer Drugs,2005,16:349-359.
[11]Li S, Gao Y, Pu K, et al. All-trans retinoic acid enhances bystander effect of suicide-gene therapy against medulloblastomas[J]. Neurosci Lett,2011,503:115-119.
[12]Kojima Y, Honda K, Hamada H, et al. Oncolytic gene therapy combined with double suicide genes for human bile duct cancer in nude mouse models[J]. J Surg Res,2009, 157:63-70.
[13]Xu B, Liu ZZ, Zhu GY, et al. Efficacy of recombinant adenovirus-mediated double suicide gene therapy in human keloid fibroblasts[J]. Clin Exp Dermatol,2008,33:322-328.
[14]Zhang Y, Wang CW, Wang ZG, et al. Construction of double suicide genes system controlled by MDR1 promoter with targeted expression in drug-resistant glioma cells[J]. J Neurooncol,2008,86:3-11.
[15]Desaknai S, Lumniczky K, Esik O, et al. Local tumour irradiation enhances the anti-tumour effect of a double-suicide gene therapy system in a murine glioma model[J]. J Gene Med, 2003,5:377-385.
[16]Bertin S, Neves S, Gavelli A, et al. Cellular and molecular events associated with the antitumor response induced by the cytosine deaminase/5-fluorocytosine suicide gene therapy system in a rat liver metastasis model[J]. Cancer Gene Ther,2007,14:858-866.
[17]Hu W, Liu W. Side populations of glioblastoma cells are less sensitive to HSV-TK/GCV suicide gene therapy system than the non-side population[J]. In Vitro Cell Dev Biol Anim, 2010,46:497-501.
[18]Engelmann C, Panis Y, Bolard J, et al. Liposomal encapsulation of ganciclovir enhances the efbcacy of herpessimplex Vims type 1 thymidine kinase suicide gene therapy against hepatic tumors in rats[J]. Human Gene Therapy,1999,10:1545-1551.
[19]Faneca H, Faustino A, Pedroso de Lima MC. Synergistic antitumoral effect of vinblastine and HSV-Tk/GCV gene therapy mediated by albumin-associated cationic liposomes[J]. J Control Release,2008,126:175-184.
[20]Pan JG, Zhou X, Luo R, et al. The adeno-associated virus-mediated HSV-TK/GCV suicide system:a potential strategy for the treatment of bladder carcinoma[J]. Med Oncol,2011.
[21]谭万龙,谢毅,吴元东,等.腺病毒介导融合双自杀基因治疗膀胱癌[J].南方医科大学学报,2006,26(5)：594-597.
[22]姚晓军,黄宗海,李强,等.CD／TK双自杀基因系统对Balb／c小鼠大肠癌的杀伤作用[J].实用医学杂志,2010,26(7)：1119-1122.
[23]张永红,唐罗生.双自杀基因CDTK载体系统对人视网膜母细胞瘤Y79细胞体外杀伤作用的研究[J].国际眼科杂志,2010,10(9)：1668-1671.
[24]孔恒,黄宗海,俞金龙,等.双自杀基因系统诱导乳腺癌细胞凋亡的体内外实验研究[J].中国现代医学杂志,2008,18(14)：1974-1978.
[25]Zhang P, Zeng H, Wei Q, et al. Improved effects of a double suicide gene system on prostate cancer cells by targeted regulation of prostate-specific membrane antigen promoter and enhancer[J].. Int J Urol,2008,15:442-448.
[26]胡铁山,李贵涛HSV-tk/GCV自杀基因系统对骨肉瘤细胞体外杀伤效应[J].第四军医大学学报,2004,25(3)：204-207.
[27]白志杰,黎玮,王亚轩,等.腺病毒介导的HSV-tk/GCV白杀基因系统靶向性治疗前列腺癌的实验研究[J].天津医科大学学报,2009,15(4)：689-691.
[28]Cottin S, Gould PV, Cantin L, et al. Gap junctions in human glioblastomas:implications for suicide gene therapy[J]. Cancer Gene Ther,2011,18:674-681.
[29]Matuskova M, Hlubinova K, Pastorakova A, et al. HSV-tk expressing mesenchymal stem cells exert bystander effect on human glioblastoma cells[J]. Cancer Lett,2010,290:58-67.
[30]Kuriyama S, Tsujinoue H, Yoshiji H. Immune response to suicide gene therapy[J]. Methods Mol Med,2004,90:353-369.
[31]Rzeszowska-Wolny J, Przybyszewski WM, et al. Ionizing radiation-induced bystander effects, potential targets for modulation of radiotherapy[J]. Eur J Pharmacol,2009, 625:156-164.
[1]Cunningham D, Allum WH, Stenning SP, et al.Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer[J]. N Engl J Med,2006,355(1):11-20.
[2]Tepper J, Krasna MJ, Niedzwiecki D, et al.Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer:CALGB 9781[J]. J Clin Oncol,2008,26(7):1086-92.
[3]Yamashita K, Sakuramoto S, Watanabe M.Genomic and epigenetic profiles of gastric cancer:potential diagnostic and therapeutic applications [J].Surg Today,2011,41(1):24-38.
[4]Guilford P, Humar B, Blair V.Hereditary diffuse gastric cancer:translation of CDH1 germline mutations into clinical practice [J].Gastric Cancer,2010,13(1):1-10
[5]Lupo-Stanghellini MT, Provasi E, Bondanza A, et al.Clinical impact of suicide gene therapy in allogeneic hematopoietic stem cell transplantation [J].Hum Gene Ther,2010, 21:241-50.
[6]Chen Y, Wang G, Kong D, et al.Double-targeted and double-enhanced suicide gene therapy mediated by generation 5 polyamidoamine dendrimers for prostate cancer [J].Mol Carcinog, 2011,1002/mc.21850.
[7]Qiu Y, Peng GL, Liu QC, et al.Selective killing of lung cancer cells using carcinoembryonic antigen promoter and double suicide genes, thymidine kinase and cytosine deaminase (pCEA-TK/CD) [JJ.Cancer Lett,2012,316(1):31-8.
[8]Nettelbeck DM, Jerome V, Miiller R.Gene therapy:designer promoters for tumour targeting[J].Trends Genet,2000,16(4):174-81.
[9]Reynolds PN, Nicklin SA, Kaliberova L, Boatman BG et al.Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo[J]. Nat Biotechnol,2001,19(9):838-42.
[10]Beck C, Uramoto H, Boren J, et al.Tissue-specific targeting for cardiovascular gene transfer. Potential vectors and future challenges [J]. Curr Gene Ther,2004,4(4):457-67.
[11]Xia K, Liang D, Tang A, et al. A novel fusion suicide gene yeast CDglyTK plays a role in radio-gene therapy of nasopharyngeal carcinoma[J]. Cancer Gene Ther,2004,11(12):790-796.
[12]孔恒,黄宗海,苏国强,等.KDR启动子驱动的双自杀基因抑制乳腺癌的体内实验研究[J].华中科技大学学报：医学版,2009,39(3)：327-30.
[13]Pantelouris EM.Absence of thymus in a mouse mutant[J].Nature,1968,217(5126):370-1.
[14]De Sousa MA, Parrott DM, Pantelouris EM.The lymphoid tissues in mice with congenital aplasia of the thymus[J].Clin Exp Immunol,1969,4(6):637-44.
[15]Pantelouris EM, Hair J.Thymus dysgenesis in nude (nu nu) mice[J].J Embryol Exp Morphol,1970,24(3):615-23.
[16]Rygaard J, Povlsen CO.Heterotransplantation of a human malignant tumour to "Nude" mice[J].Acta Pathol Microbiol Scand,1969,77(4):758-60.
[17]Rygaard J, Povsen CO. Heterotransplantation of a human malignant tumour to "nude" mice 1969 APMIS[J].2007,115(5):604-6.
[18]Gallie BL, Albert DM, Wong JJ, et al. Heterotransplantation of retinoblastoma into the athymic "nude" mouse[J].Invest Ophthalmol Vis Sci,1977,16(3):256-9.
[19]Giovanella BC, Fogh J.The nude mouse in cancer research[J].Adv Cancer Res,1985, 44:69-120.
[20]Sharkey FE, Fogh J.Considerations in the use of nude mice for cancer research[J].Cancer Metastasis Rev,1984,3(4):341-60.
[21]Fogh J, Fogh JM, Orfeo T.One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice[J].J Natl Cancer Inst.1977 Jul;59(1):221-6.
[22]Li Y, Li B, Xiang CP, et al.Characterization of gastric cancer models from different cell lines orthotopically constructed using improved implantation techniques[J].World J Gastroenterol.2012,18(2):136-43.
[23]Follet J, Remy L, Hesry V, et al.Adaptation to statins restricts human tumour growth in Nude mice[J].BMC Cancer,2011,11:491.
[24]Sumida T, Kitadai Y, Shinagawa K, et al.Anti-stromal therapy with imatinib inhibits growth and metastasis of gastric carcinoma in an orthotopic nude mouse model[J].Int J Cancer. 2011 May 1;128(9):2050-62.
[25]Zhao G, Guo LL, Xu JY, et al.Integrin-linked kinase in gastric cancer cell attachment, invasion and tumor growth [J]. World J Gastroenterol,2011,17(30):3487-96.
[26]Li J, Mo ML, Chen Z, Yang J, et al.HSulf-1 inhibits cell proliferation and invasion in human gastric cancer[J].Cancer Sci,2011,102(10):1815-21.
[27]Cui Y, Urschel JD, Petrelli NJ. Effect of pyloric drainage on the healing of esophagogastric anastomoses in rats. Can J Surg,2000,43(6):456-458.
[28]张永红,,唐罗生.双自杀基因CDTK载体系统对裸小鼠Y79细胞皮下移植瘤的杀伤作用[J].国际眼科杂志,2010,10(10)：1871-1873.
[29]Chen Y, Wang G, Kong D, et al.Double-targeted and double-enhanced suicide gene therapy mediated by generation 5 polyamidoamine dendrimers for prostate cancer[J].Mol Carcinog 2011.10.1002/mc.21850
[30]Qiu Y, Peng GL, Liu QC, et al.Selective killing of lung cancer cells using carcinoembryonic antigen promoter and double suicide genes, thymidine kinase and cytosine deaminase (pCEA-TK/CD) [J].Cancer Lett,2012,316:31-38.
[1]Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics,2002[J].CA Cancer J Clin, 2005,55:74-108.
[2]Roesomando AJ, Sanghera JS, Marsden LA, et al.Biochemical characterization of a family of scrine/threonine protein kinascs regulated by tyrosine and scrine/threonine phosphorylations [J] J Biol Chem,1991,266:20270-20275.
[3]Shah MA, Schwartz GK.Treatment of metastatic esophagus and gastric cancer [J].Semin Oncol,2004,31:574-587.
[4]Bornschein J, Rokkas T, Selgrad M, et al. Gastric cancer:clinical aspects, epidemiology and molecular background [J].Helicobacter,2011,1:45-52.
[5]Vogiatzi P, Vindigni C, Roviello F, et a 1.Deciphering the underlying genetic and epigenetic events leading to gastric carcinogenesis[J]. J Cell Physiol,2007,211:287-295.
[6]Crew KD, Neugut Al. Epidemiology of gastric cancer [J]. World J Gastroenterol 2006, 12:354-362.
[7]Shikata K, Doy Y, Yonemoto K, et al. Population-based prospective study of the combined influence of cigarette smoking and Helicobacter pylori infection on gastric cancer incidence:the Hisayama study[J]. Am J Epidemiol,2008,12:1409-1415.
[8]Fan H, Liu D, Qiu X, et al. A functional polymorphism in the DNA methyltransferase-3A promoter modifies the susceptibility in gastric cancer but not in esophageal carcinoma[J]. BMC Med,2010,8:12.
[9]Samuel MS, Suzuki H, Buchert M, et al. Elevated Dnmt3a activity promotes polyposis in Ape Min mice by relaxing extracellular restrains on Wnt signaling[J]. Gastroenterology, 2009; 137:902-13.
[10]Ding WJ, Fang JY, Chen XY, et al. The expression and clinical significance of DNA methyltransferase proteins in human gastric cancer[J]. Dig Dis Sci,2008,53:2083-2089.
[11]Ju H, Lim B, Kim M, et al. A regulatory polymorphism at position-309 in PTPRCAP is associated with susceptibility to diffuse-type gastric cancer and gene expression[J]. Neoplasia,2009,11:1340-1347.
[12]Motoya S, Kitamura K, Matsuda A, et al.Interaction between CD45-AP and protein-tyrosine kinases involved in T cell receptor signaling[J]. J Biol Chem,1999,274: 14392-14399.
[13]Avizienyte E, Wyke AW, Jones RJ, et al. SRC-induced de-regulation of E-cadherin in colon cancer cells requires integrin signaling[J]. Nat Cell Biol,2002,4:632-638.
[14]Sakamoto H, Yoshimura K, Saeki N, et al. Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer[J]. Nat Genet,2008,40:730-740.
[15]Lu Y, Chen J, Ding Y, et al. Genetic variation of PSCA gene is associated with the risk of both diffuse and intestinal-type gastric cancer in a Chinese population[J]. Int J Cancer, 2010;127:2183-9.
[16]Ke Q, Liang J, Wang LN, et al. Potentially functional polymorphisms of the vascular endothelial growth factor gene and risk of gastric cancer[J]. Mol Carcinog,2008,47:647-651.
[17]Zhao R, Liu XQ, Wu XP, et al. Vascular endothelial growth factor (VEGF) enhances gastric carcinoma invasiveness via integrin alpha (v) beta6[J]. Cancer Lett,2010,287:150-156.
[18]Guan X, Zhao H, Niu J, Tang D, Ajani JA, Wei Q. The VEGF-634G＞C promoter polymorphism is associated with risk of gastric cancer[J]. BMC Gastroenterol,2009,9:77.
[19]Tahara T, Shibata T, Nakamura M, et al. Effect of polymorphisms in the 3(?) untranslated region (3(?)-UTR) of vascular endothelial growth factor gene on gastric cancer and peptic ulcer diseases in Japan[J]. Mol Carcinog,2009,48:1030-1037.
[20]Caldecott KW, Tucker JD, Stanker LH, Thompson LH. Characterization of the XRCC1-DNA ligase III complex in vitro and its absence from mutant hamster cells [J]. Nucleic Acids Res,1995,23:4836-4843.
[21]Hao B, Miao X, Li Y, et al. A novel T-77C polymorphism in DNA repair gene XRCC1 contributes to diminished promoter activity and increased risk of non-small cell lung cancer[J].Oncogene,2006,25:3613-3620.
[22]Corso G, Marrelli D, Pedrazzani C, et al. Gastric cardia carcinoma is associated with the promoter-77T>C gene polymorphism of X-ray cross-complementing group 1 (XRCC1) [J].J Gastrointest Surg,2009,13:2233-2238.
[23]Ross JS, McKenna BJ. The HER-2/neu oncogene in tumours of the gastrointestinal tract[J]. Cancer Invest,2001,19:554-568.
[24]Kozma L, Kiss I, Hajdu J, et al.C-myc amplification and cluster analysis in human gastric carcinoma[J].Anticancer Res,2001,21:707-710.
[25]Pan G, Lv Hui, Ren H, et al. Elevated expression of semaphoring 5A in human gastric cancer and its implication in carcinogenesis[J].Life Sci,2010;86:139-44.
[26]Florou D, Papadopoulos IN, Scorilas A. Molecular analysis and prognostic impact of the novel apoptotic gene BCL2L12 in gastric cancer[J]. Biochem Biophys Res Commun, 2010,391:214-218.
[27]Berger SL. The complex language of chromatin regulation during transcription[J]. Nature, 2007,447:407-412.
[28]Zeng J, Ge Z, Wang L, et al. The histone demethylase RBP2 is overexpressed in gastric cancer and its inhibition triggers senescence of cancer cells[J]. Gastroenterology,2010,138: 981-992.
[29]Vogiatzi P, Vindigni C, Roviello F, et al. Deciphering the underlying genetic and epigenetic events leading to gastric carcinogenesis[J]. J Cell Physiol,2007,211:287-295.
[30]Crew KD, Neugut Al. Epidemiology of gastric cancer[J]. World J Gastroenterol,2006,12: 354-362.
[31]Pinheiro H, Bordeira-Carric,o R, Seixas S, et al. Allele-specific CDH1 downregulation and hereditary diffuse gastric cancer[J].Hum Mol Genet,2010,5:943-952.
[32]Dohi O, Takada H, Wakabayashi N, et al. Epigenetic silencing of RELN in gastric cancer[J]. Int J Oncol,2010,36:85-92.
[33]Du P, Ye HR, Gao J, et al. Methylation of PTCH1a gene in a subset of gastric cancers[J]. World J Gastroenterol,2009,15:3799-3806.
[34]Ye Q, Shen Y, Wang X, et al. Hypermethylation of HLC class Ⅰ is associated with HLA class Ⅰ down-regulation in human gastric cancer[J]. Tissue Antigens,2010,75:30-39.
[35]Agarwal R, Mori Y, Cheng Y, et al. Silencing of claudin-11 is associated with increased invasiveness of gastric cancer cells[J].PLoS ONE,2009,4:8002.
[36]Zhao C, Bu X, Zhang N, et al. Downregulation of SFRP5 expression and its inverse correlation with those of MMP-7 and MTI-MMP in gastric cancer [J]. BMC Cancer, 2009,9:224.
[37]Rhyu MG, Park WS, Meltzer SJ. Microssatelite instability occurs frequently in human gastric carcinoma[J]. Oncogene,1994,1:29-32.
[38]Carneiro F, Oliveira C, Leite M, Seruca R. Molecular targets and biological modifiers in gastric cancer[J]. Semin Diagn Pathol,2008,4:274-287.
[39]Velho S, Oliveira C, Paredes J, et al. Mixed lineage kinase 3gene mutations in mismatch repair deficient gastrointestinal tumours [J]. Hum Mol Genet,2010,19:697-706.
[40]Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, Karson EM, Lotze MT, Yang JC, Topalian SL, et al. Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction[J]. N Engl J Med,1990,323(9):570-578.
[41]Freeman SM, Abboud CN, Whartenby KA, et al. The "bystander effect":tumor regression when a fraction of the tumor mass is genetically modified [J]. Cancer Res,1993,53: 5274-5283.
[42]Matono S, Tanaka T, Sueyoshi S,et al.Bystander effect in suicide gene therapy is directly proportional to the degree of gap junctional intercellular communication in esophageal cancer[J].Int J Oncol,2003,23:1309-1315.
[43]Oshiro TM, Enobe CS,Ara jo CA,et al.PAS-1,a protein affinitypurified from Ascafis suunl worms,maintains the ability to modulate the immune response to a bystander antigen[J]. Immunol Cell Biol,2006,84:138-144.
[44]Kimm M,Sami L,Esko A,et al.Evaluation of herp es simplex thymidine kinase mediated gene therapy in experimental pancreatic cancer[J].J Gene,2000,2:361-367.
[45]Pan X,Li ZS,Xu GM,et al.Adenovirus-mediated gene transfer in the treatment of pancrealic cancer[J].Pancreas,2003,26:274-278.
[46]Puhlmann M.Gnant M,Brown CK,et al.Thymidine kinase deleted vaccinia virus expressing pufine nucleeside phosphorylase as a vector for tumor directed gene therapy[J]. Hum Gene Ther,1999,10:649-657.
[47]Tahara E, Semba S, Tahara H. Molecular biological observations in gastric cancer[J]. Semin Oncol,1996,23:307-315.
[48]Baker SJ, Markowitz S, Fearon ER, et al.Vogelstein B.Suppression of human colorectal carcinoma cell growth by wildtype p53[J]. Science,1990,249:912-915.
[49]Mercer WE, Shields MT, Amin M, et al. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53[J]. Proc Natl Acad Sci USA,1990,87:6166-6170.
[50]Matozaki T, Sakamoto C, Suzuki T, et al. p53 gene mutations in human gastric cancer: wild-type p53 but not mutant p53 suppresses growth of human gastric cancer cells[J]. Cancer Res,1992,52:4335-4341.
[51]Ohashi M, Kanai F, Ueno H, et al. Adenovirus mediated p53 tumour suppressor gene therapy for human gastric cancer cells in vitro and in vivo[J]. Gut,1999,44:366-371
[52]Tamura GAlterations of tumor suppressor and tumor-related genes in the development and progression of gastric cancer [J].World J Gastroenterol,2006,12:192-198.
[53]Chaudhary KS, Abel PD, Stamp GWH, Lalani EN. Differential expression of cell death regulators in response to thapsigargin and adriamycin in Bcl-2 transfected DU145 prostatic cancer cells. J Pathol,2001,193:522-529.
[54]Jeong Yw,Kim KS,Oh JY,et al.Exogenous wild type p16INK4A gene induces delayed cell proliferation and promotes chemosensitivity through decreased pRB and increased E2F-1 expressions[J].Int J Mol Med,2003;12:61-65.
[55]Guo C,Ding J,Yao I,el al.Tumor suppressor gene Runx3 sensitizes gastric cancer cells to chemotherapeutic drugs by downregulating Bcl-2,MDR-I and MRP-1[J].Int J Cancer,2005, 116:155-160.
[56]Sun HW, Tong SL, He J, et al. RhoA and RhoC-siRNA inhibit the proliferation and invasiveness activity of human gastric carcinoma by Rho/PI3K/Akt pathway. World J Gastroenterrol,2007,13:3517-3522.
[57]Ueda M, Kokura S, Imamoto E, et al. Blocking of NF-B activation enhances the tumor necrosis factorkB-induced apoptosisof a human gastric cancer cell line. Cancer Lett,2003, 193:177-182.
[58]Hang Y, Zheng YC, Cao Y, et al. Suppression of gastric cancer growth by adenovirus-mediated transfer of the PTEN gene.World J Gastroenterol,2005,11:2224-2229.
[59]Tu SP, Jiang XH, Lin MCM, et al. Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer.Cancer Res,2003,63:7724-7732
[60]Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature,1996,383:787-793.
[61]Kosaka K,Yashiro M,Sakate Y,et al.CD80 gene therapy for lymph node involvement by gastric carcinoma[J].Int J Oncol,2004,25:1319-1325.
[62]Tanaka H,Yashiro M.Sunami T.et al.Lipid-mediated genetransfeetion of intercelular adhesion molecule suppresses the peritoneal metastasis of gastric carcinoma[J].Im J Mol Med,2002,10:613.
[63]Kircheis R,Kupcu Z,Wallner G,et al.Cytokine gene-modified tumor cells for prophylactic and therapeutic vaccination:IL-2, IFN-gamma,or combination IL-2+IFN-gamma[J]. Cytokines Cell Mol Ther,1998,4:95-103.
[64]Motoi F,Sunamura M,Ding L,et a 1.Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication competent adenovirus[J].Hum Gene Ther, 2000,11:223-235.
[65]Wu J, Shi YQ, Wu KC, et al. Angiostatin up-regulation in gastric cancer cell SGC7901 inhibits tumorigenesis in nude mice. World J Gastroenterol,2003,9:59-64.
[66]Nie MM, Fang GE, Wang XH, et al.Anti-tumor effect of gene-viral therapeutic system CNHK300-murine endostatin on nude mouse gastric cancer. Zhonghua Wei Chang Wai Ke Za Zhi,2007,10:565-569.
[67]Fujiuchi S, Yamazaki Y, Fujita Y, et al. S-nitrosoglutathione (SNOG) accumulates hypoxia inducible factor-1 alpha in main pulmonary artery endothelial cells but not in micro pulmonary vessel endothelial cells. Adv Exp Med Biol,2006,580:63-71.
[68]Kim R, Minami K, Nishimoto N, Toge T. Enhancement of antitumor effect by intratumoral administration of bax gene in combination with anticancer drugs in gastric cancer. Int J Oncol,2001; 18:363-367.
[69]Khare PD, Shao-Xi L, Kuroki M, et al. Specifically targeted killing of carcinoembryonic antigen (CEA)-expressing cells by a retroviral vector displaying single-chain variable fragmented antibody to CEA and carrying the gene for inducible nitric oxide synthase[J]. Cancer Res 2001;61:370-375.
[70]Tanaka T, Huang J, Hirai S, et al. Carcinoembryonic antigentargeted selective gene therapy for gastric cancer through FZ33 fiber-modified adenovirus vectors [J]. Clin Cancer Res, 2006,12:3803-3813.
[71]Heideman DAM, Snijders PJF, Craanen ME, et al. Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors [J]. Cancer Gene Ther,2001,8:342-351.
[72]Williams C, Shattuck-Brandt RL, DuBois RN. The role of COX-2 in intestinal cancer[J]. Ann N Y Acad Sci,1999,889:72-83.
[73]Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M.Expression of cyclooxygenase-2 in human gastric carcinoma[J]. Cancer Res,1997,57:1276-1280.
[74]Yamamoto M, Alemany R, Adachi Y, Grizzle WE, Curiel DT.Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers[J]. Mol Ther,2001,3:385-394.
[75]Luo XR, Li JS, Niu Y, Miao LTargeted killing effects of double CD and TK s uicide genes controlled by survivin promoter on gastric cancer cell[J]. Mol Biol Rep,2011,38(2): 1201-1207.